## PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

<sup>Pr</sup>KISQALI<sup>®</sup>

ribociclib (as ribociclib succinate) Tablets, 200 mg, oral

Protein kinase inhibitor, L01XE42 Anti-neoplastic agent

Novartis Pharmaceuticals Canada Inc. 700 Saint-Hubert St., Suite 100 Montreal, Quebec H2Y 0C1 www.novartis.ca Date of Initial Authorization: Mar 2, 2018

Date of Revision: Feb 10, 2023

Novartis Version: Mar 10, 2023

Submission Control Number: 262779

#### **RECENT MAJOR LABEL CHANGES**

Section 1 Indications	February 2023
Section 4 Dosage and Administration	February 2023
Section 7 Warnings and Precautions	November 2022

#### TABLE OF CONTENTS

Section	s or su	bsections that are not applicable at the time of authorization are not listed.	
RECEN	Т МАЈ	OR LABEL CHANGES	2
TABLE	OF CO	NTENTS	2
PART I	: HEAL	TH PROFESSIONAL INFORMATION	4
1	INDIC	ATIONS	4
	1.1	Pediatrics	4
	1.2	Geriatrics	4
2	CONT	RAINDICATIONS	4
3	SERIC	US WARNINGS AND PRECAUTIONS BOX	4
4	DOSA	GE AND ADMINISTRATION	5
	4.1	Dosing Considerations	5
	4.2	Recommended Dose and Dosage Adjustment	5
	4.4	Administration1	0
	4.5	Missed Dose1	0
5	OVER	DOSAGE1	0
6	DOSA	GE FORMS, STRENGTHS, COMPOSITION AND PACKAGING1	0
7	WAR	NINGS AND PRECAUTIONS1	1
	7.1	Special Populations1	6
	7.1.1	Pregnant Women1	6
	7.1.2	Breast-feeding1	6
	7.1.3	Pediatrics1	7
	7.1.4	Geriatrics1	7
	7.1.5	Hepatic Impairment:1	7
8	ADVE	RSE REACTIONS1	7

	8.1	Adverse Reaction Overview	17		
	8.2	Clinical Trial Adverse Reactions	19		
	8.3	Less Common Clinical Trial Adverse Reactions	25		
	8.4 Quan	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other titative Data	26		
	8.5	Post-Market Adverse Reactions	29		
9	DRUG	G INTERACTIONS	29		
	9.2	Drug Interactions Overview	29		
	9.4	Drug-Drug Interactions	29		
	9.5	Drug-Food Interactions	33		
	9.6	Drug-Herb Interactions	33		
	9.7	Drug-Laboratory Test Interactions	33		
10	CLINI	CAL PHARMACOLOGY	33		
	10.1	Mechanism of Action	33		
	10.2	Pharmacodynamics	34		
	10.3	Pharmacokinetics	35		
11	STOR	AGE, STABILITY AND DISPOSAL	38		
12	SPECI	AL HANDLING INSTRUCTIONS	38		
PART I	I: SCIE	NTIFIC INFORMATION	39		
13	PHAR	MACEUTICAL INFORMATION	39		
14	CLINI	CAL TRIALS	40		
	14.1 (	Clinical Trials by Indication	40		
	14.2 (	Comparative Bioavailability Studies	59		
15	MICROBIOLOGY				
16	NON-CLINICAL TOXICOLOGY				
PATIEN		DICATION INFORMATION	65		

## PART I: HEALTH PROFESSIONAL INFORMATION

## **1** INDICATIONS

KISQALI<sup>®</sup> (ribociclib tablets) is indicated, in combination with:

- an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy;
- In pre/perimenopausal women, or men, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
- fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.

#### 1.1 Pediatrics

#### Pediatrics (≤ 18 years of age):

There are limited data in pediatric patients and the safety and efficacy of KISQALI in this population have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

#### 1.2 Geriatrics

#### Geriatrics ( $\geq$ 65 years of age):

Of 334 patients who received KISQALI plus letrozole in the pivotal phase III study A2301, 150 patients (45%) were  $\geq$  65 years of age; no major differences in safety of KISQALI were observed between patients < 65 and  $\geq$  65 years of age. Of 483 patients who received KISQALI plus fulvestrant in the phase III study F2301, 226 patients (46.8%) were  $\geq$ 65 years of age and 65 patients (13.5%) were  $\geq$ 75 years of age. No major differences in safety of KISQALI were observed between these patients and younger patients (see <u>4 DOSAGE AND ADMINISTRATION</u>).

## 2 CONTRAINDICATIONS

- Patients with hypersensitivity to this drug or to any ingredient in the formulation. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION and PACKAGING section.
- Patients with untreated congenital long QT syndrome, a QTcF interval of ≥450 msec at baseline, and those who are at significant risk of developing QTc prolongation (see <u>7 WARNINGS and</u> <u>PRECAUTIONS</u>).

## **3** SERIOUS WARNINGS AND PRECAUTIONS BOX

#### **Serious Warnings and Precautions**

- QT interval prolongation (see 7 WARNINGS AND PRECAUTIONS)
- Hepatotoxicity (see 7 WARNINGS AND PRECAUTIONS)
- Neutropenia (see 7 WARNINGS AND PRECAUTIONS)

• KISQALI (ribociclib tablets) should be administered by health professionals experienced with anti-cancer agents

## 4 DOSAGE AND ADMINISTRATION

#### 4.1 Dosing Considerations

Treatment of pre- or peri-menopausal women, or men, with KISQALI combination should include an LHRH agonist according to local clinical practice standards.

Dose adjustment is required in patients with moderate and severe hepatic impairment (see <u>4.2</u> <u>Recommended Dose and Dosage Adjustments</u>, and <u>10 CLINICAL PHARMACOLOGY</u>)

Dose adjustment is required in patients with severe renal impairment (see <u>4.2 Recommended Dose and</u> <u>Dosage Adjustments</u>, and <u>10 CLINICAL PHARMACOLOGY</u>).

Concomitant use of KISQALI should be avoided with strong CYP3A inhibitors. KISQALI dose adjustment is required if a strong CYP3A inhibitor must be co-administered (see <u>4.2 Recommended Dose and Dosage Adjustments</u>, and <u>10 CLINICAL PHARMACOLOGY</u>).

#### 4.2 Recommended Dose and Dosage Adjustment

Treatment with KISQALI should be initiated by a physician experienced in the use of anticancer therapies.

#### Recommended dose

The recommended dose of KISQALI is 600 mg (3 x 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food (see <u>10 CLINICAL PHARMACOLOGY</u> and <u>9.5 Drug-Food</u> <u>Interactions sections</u>).

For dosing and co-administration of KISQALI with an aromatase inhibitor refer to the applicable Product Monograph for detailed conditions of use.

Patients should take their dose of KISQALI and the aromatase inhibitor at approximately the same time each day, preferably in the morning.

When co-administered with KISQALI, the recommended dose of fulvestrant is 500 mg administered intramuscularly on days 1, 15 and 29, and once monthly thereafter. Refer to the Product Monograph for fulvestrant for detailed conditions of use.

#### **Dose Adjustments for Adverse Drug Reactions**

Management of severe or intolerable adverse drug reactions (ADRs) may require temporary dose interruption, reduction, or permanent discontinuation of KISQALI. If dose reduction is required, the recommended dose reduction guidelines for adverse drug reactions (ADRs) are listed in Table 1.

#### Table 1 Recommended dose modification guidelines for adverse drug reactions

	KISQALI Dose Number of Tablets			
Starting dose	600 mg/day	3 × 200 mg tablets		
First dose reduction	400 mg/day	2 × 200 mg tablets		
Second dose reduction	200 mg/day*	1 × 200 mg tablet		

\*If further dose reduction below 200 mg/day is required, discontinue the treatment.

Tables 2, 3, 4, 5 and 6 summarize recommendations for dose interruption, reduction, or discontinuation of KISQALI in the management of specific ADRs. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment (see <u>7 WARNINGS AND PRECAUTIONS</u> and <u>8 ADVERSE REACTIONS</u> sections).

Neutropenia	<b>Grade 1 or 2</b> (ANC <sup>1</sup> 1,000/mm <sup>3</sup> – <lln<sup>2)</lln<sup>	<b>Grade 3</b> (ANC <sup>1</sup> <1,000/mm <sup>3</sup> )	Grade 3 febrile* neutropenia	Grade 4 (ANC <sup>1</sup> <500/mm <sup>3</sup> )	
	No dose adjustment is required.	Interrupt KISQALI until recovery to Grade ≤2. Resume KISQALI at the same dose level.	Interrupt KISQALI until recovery of neutropenia to Grade ≤2. Resume KISQALI at the next lower dose level.	Interrupt KISQALI until recovery to Grade ≤2. Resume KISQALI at the next lower dose level.	
		If toxicity recurs at Grade 3, interrupt KISQALI dose until recovery to Grade ≤2, then resume KISQALI at the next lower dose level.			
	Perform Complete Blood Counts (CBC) before initiating treatment with KISQALI. After initiating treatment with KISQALI, monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated.				
*Grade 3 neutropenia with a single episode of fever >38.3°C or a sustained temperature above 38°C for more than one hour Grading according to CTCAE Version 4.03 CTCAE=Common Terminology Criteria for Adverse Events. <sup>1</sup> : absolute neutrophil count <sup>2</sup> : lower limit of normal					

Table 2 Dose modification and management for neutropenia

## Table 3 Dose modification and management for hepatobiliary toxicity

AST and/or ALT elevations from baseline*, without increase in total	Grade 1 (>ULN – 3 x ULN)	Grade 2 (>3 to 5 x ULN)	Grade 3 (>5 to 20 x ULN)	Grade 4 (>20 x ULN)			
bilirubin above 2 x ULN	No dose adjustment is required.	Baseline at <grade 2:<br="">Interrupt KISQALI until recovery to ≤ baseline grade, then resume KISQALI at same dose level. If Grade 2 recurs, resume KISQALI at next lower dose level. </grade>	Interrupt KISQALI until recovery to ≤ baseline grade, then resume at next lower dose level. If Grade 3 recurs, discontinue KISQALI.	Discontinue KISQALI			
Combined elevations in AST and/or ALT together with total bilirubin increase, in the absence of cholestasis	If patients develop ALT and/or AST >3 x ULN along with total bilirubin >2 x ULN irrespective of baseline grade, discontinue KISQALI.						
Perform LFTs before initiating treatment with KISQALI. After initiating treatment with KISQALI, monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and monitor periodically as clinically indicated. If Grade ≥2 abnormalities are observed, more frequent monitoring, for example, twice weekly, is recommended.							
	*Baseline = prior to treatment initiation. Grading according to CTCAE Version 4.03 CTCAE=Common Terminology Criteria for Adverse Events.						

## Table 4 Dose modification and management for QT prolongation

ECGs with QTcF interval >480 ms	<ol> <li>Interrupt the KISQALI dose</li> <li>If QTcF interval prolongation resolves to &lt;481 ms, resume KISQALI at the next lower dose level</li> </ol>
	<ol> <li>If QTcF interval ≥481 ms recurs, interrupt the KISQALI dose until QTcF interval resolves to &lt;481 ms; and then resume KISQALI at next lower dose level</li> </ol>
ECGs with QTcF interval >500 ms	If QTcF interval is greater than 500 ms, interrupt KISQALI until QTcF interval reaches <481 ms then resume KISQALI at next lower dose level
Torsade de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia	Permanently discontinue KISQALI
Assess ECG prior to initia	ition of treatment.

After initiating treatment with KISQALI, repeat ECGs on Day 14 of the first cycle, at the beginning of Cycle 2, at regular intervals thereafter during steady-state treatment (e.g., at approximately day 14 of the cycle), and whenever clinically indicated. In case of QTc prolongation at any given time during treatment, more frequent ECG monitoring is recommended. Serum electrolytes (including potassium, calcium, phosphorous and magnesium) should be assessed prior to initiation of treatment, at regular intervals in later cycles, and whenever clinically indicated with abnormalities corrected prior to commencement/ resumption of treatment.

#### Table 5 Dose modification and management for ILD/Pneumonitis

ILD/pneumonitis	Grade 1	Grade 2	Grade 3 or 4
	(asymptomatic)	(symptomatic)	(severe)
	No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.	Interrupt Kisqali until recovery to Grade ≤1, then resume Kisqali at the next lower dose level*.	Discontinue Kisqali

Grading according to CTCAE Version 4.03.

\* An individualized benefit-risk assessment should be performed when considering resuming Kisqali

ILD = Interstitial Lung Disease

## Table 6 Dose modification and management for other toxicities\*

Other toxicities	Grade 1 or 2	Grade 3	Grade 4
	No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.	Interrupt KISQALI dose until recovery to Grade ≤1, then resume KISQALI at the same dose level. If Grade 3 recurs, resume KISQALI at the next lower dose level.	Discontinue KISQALI.
	ia, hepatobiliary toxicity, QT inter CTCAE Version 4.03. CTCAE=Com	val prolongation and ILD/Pne	

Refer to the Product Monograph for the co-administered aromatase inhibitor, fulvestrant or LHRH agonist for dose modification guidelines in the event of toxicity and other relevant safety information.

## Dose modification for use of KISQALI with strong CYP3A inhibitors

Concomitant use of KISQALI should be avoided with strong CYP3A inhibitors and an alternative concomitant medication should be considered with low potential for CYP3A inhibition. If a strong CYP3A inhibitor must be co-administered, the KISQALI dose should be reduced to 200 mg once daily. If the strong inhibitor is discontinued, the KISQALI dose should be changed (after at least 5 elimination half-lives of the strong CYP3A inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor (see <u>7 WARNINGS AND PRECAUTIONS</u> and <u>9 DRUG INTERACTIONS</u> section).

#### Special populations

#### Patients with hepatic impairment:

Based on a hepatic impairment study in healthy subjects and non-cancer subjects with impaired hepatic function, no adjustment of the starting dose is necessary in patients with mild hepatic impairment (Child-Pugh class A).

A dose adjustment is required in patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) and the starting dose of 400 mg is recommended (see <u>10 CLINICAL</u> <u>PHARMACOLOGY</u> section). However, in the Phase III trial, the efficacy and safety of KISQALI have not been studied in breast cancer patients with moderate and severe hepatic impairment; initiate KISQALI treatment in these patients only when perceived benefit outweighs potential risk.

Refer to the appropriate Product Monograph for the aromatase inhibitor, fulvestrant or the LHRH agonist for dose modifications related to hepatic impairment.

#### Patients with renal impairment:

KISQALI has not been studied in breast cancer patients with severe renal impairment. Based on population pharmacokinetic analysis, and data from cancer patients in clinical trials, no adjustment of the starting dose is necessary in patients with mild or moderate renal impairment.

Based on a renal impairment study in non-cancer subjects with severe renal impairment and normal renal function, a starting dose of 200 mg is recommended for patients with severe renal impairment. Caution should be used in patients with severe renal impairment with close monitoring for signs of toxicity (see <u>10 CLINICAL PHARMACOLOGY</u> section); initiate KISQALI treatment in these patients only when perceived benefit outweighs potential risk.

**Pediatrics (< 18 years of age):** There are limited data in pediatric patients and the safety and efficacy of KISQALI in this population have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

Geriatrics (≥ 65 years of age): No adjustment of the starting dose is required in patients over 65 years of age.

## 4.4 Administration

KISQALI and aromatase inhibitors or fulvestrant should be taken at approximately the same time each day, preferably in the morning. KISQALI tablets should be swallowed whole (tablets should not be chewed, crushed or split prior to swallowing). Tablets that are broken, cracked, or otherwise not intact should not be ingested.

#### 4.5 Missed Dose

If the patient vomits or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time.

## 5 OVERDOSAGE

There is limited experience with reported cases of KISQALI overdose in humans. Patients should be closely monitored for adverse drug reactions. General symptomatic and supportive measures, such as ECG monitoring, should be initiated in all cases of overdosage.

For management of a suspected drug overdose, contact your regional poison control centre.

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Oral	Tablet 200 mg ribociclib (as ribociclib succinate) <i>Strength:</i> Each tablet contains 200 mg ribociclib (as ribociclib succinate) <i>Medicinal ingredient:</i> ribociclib succinate	No clinically relevant non-medicinal ingredients: Excipients <i>Tablet core:</i> Colloidal silicon dioxide; crospovidone (Type A); low-substituted hydroxypropylcellulose; magnesium stearate; microcrystalline cellulose; <i>Coating material:</i> Iron oxide black (E172); iron oxide red (E172); lecithin (soy) (E322); polyvinyl alcohol (partially hydrolysed); talc; titanium dioxide (E171); xanthan gum.

## COMPOSITION:

KISQALI (ribociclib tablets) is a light greyish violet film-coated tablet, unscored, round, curved with beveled edge, debossed with "RIC" on one side and "NVR" on the other side.

## PACKAGING:

KISQALI (ribociclib tablets) is supplied in unit dose blisters in the following pack sizes: 21, 42 and 63 tablets.

KISQALI TABLETS			
Package Size	Package Configuration		
Pack of 63:	Blister pack containing 21 tablets (3 tablets for 600mg dose).		
	3 Blister packs per outer container		
Pack of 42:	Blister pack containing 14 tablets (2 tablets for 400 mg dose).		
	3 Blister packs per outer container		
Pack of 21:	Blister pack containing 21 tablets (1 tablet for 200mg dose).		
	1 Blister pack per outer container		

## 7 WARNINGS AND PRECAUTIONS

Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.

#### **Carcinogenesis and Mutagenesis**

In the 2 year rat carcinogenicity study, increase incidence of adenocarcinoma in the uterus/cervix and follicular tumors in the thyroid glands of males have been observed.

These effects may be related to prolonged hypoprolactinemia secondary to CDK4 inhibition of lactotrophic cell function in the pituitary gland, altering the hypothalamus-pituitary-gonadal axis. Considering important differences between rodents and humans with regard to synthesis and role of prolactin, it is not certain whether this mode of action is expected to have consequences in humans (see <u>16 NON-CLINICAL TOXICOLOGY</u> section).

#### Cardiovascular

#### QT interval prolongation

KISQALI has shown a concentration-dependent prolongation of the QTc interval, with the mean increase from baseline of approximately 19.6 msec (90% CI 18.0, 21.2) during steady-state treatment at 2 hours post-dosing on Day 15 in the phase III A2301 clinical trial (see <u>10 ACTION AND CLINICAL</u> <u>PHARMACOLOGY</u> section). One event of sudden death (0.3%) occurred during treatment with KISQALI plus letrozole in the phase III clinical trial (A2301) in a patient with Grade 2 QT prolongation and Grade 3 hypokalemia. No cases of sudden death were reported in studies E2301 or F2301. In the pooled phase III clinical studies, in patients with advanced or metastatic breast cancer who received the KISQALI plus any combination partners, 15 patients (1.4%) had >500 ms post-baseline QTCF value, and 61 patients (5.8%) had a >60 msec QTCF interval increase from baseline.

ECG assessments during steady-state were collected on Cycle 1 Day 15 in the three phase III clinical studies and were also collected on Cycle 3 Day 15 in study E2301 and Cycle 2 Day 15 in study F2301.

QTc prolongation can lead to an increased risk of ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes is a polymorphic ventricular tachyarrhythmia. Generally, the risk of Torsade de Pointes increases with the magnitude of QTc prolongation produced by the drug. Torsade de Pointes may be asymptomatic or experienced by the patient as dizziness, palpitations, syncope, or seizures. If sustained, Torsade de Pointes can progress to ventricular fibrillation and sudden cardiac death.

Risk factors for Torsade de Pointes in the general population include, but are not limited to, the following: female gender, age  $\geq$  65 years, baseline prolongation of the QTc interval; presence of genetic variants affecting cardiac ion channels or regulatory proteins, especially congenital long QT syndromes; family history of sudden cardiac death at <50 years of age; cardiac disease (e.g., myocardial ischemia or infarction, congestive heart failure, cardiomyopathy, conduction system disease); history of arrhythmias; electrolyte disturbances (e.g., hypokalemia, hypomagnesemia, hypocalcemia) or conditions leading to electrolyte disturbances (e.g., persistent vomiting, eating disorders); bradycardia; acute neurological events (e.g., intracranial or subarachnoid hemorrhage, stroke, intracranial trauma); diabetes mellitus; and autonomic neuropathy.

Treatment with KISQALI is contraindicated in patients with untreated congenital long QT syndrome; baseline prolongation of the QTc interval; and patients at risk of developing QTc prolongation (for example, uncontrolled, significant cardiac disease including but not limited to, recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias). Treatment with KISQALI should be avoided in patients with uncorrected hypokalemia, hypomagnesemia, or hypocalcemia. Hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior to initiation or continuation of KISQALI treatment.

Particular care should be exercised when administering KISQALI to patients who are suspected to be at an increased risk of experiencing Torsade de Pointes during treatment with a QTc-prolonging drug.

Assess electrocardiography (ECG) before initiating KISQALI and repeat at approximately Day 14 of the first cycle, at the beginning of the second cycle, at regular intervals thereafter during steady-state treatment (at approximately Day 14 of the cycle) and whenever clinically indicated. QTc prolongation is expected to be maximal during days 8 – 21 of the 28-day cycle. Assess serum electrolytes prior to the initiation of KISQALI treatment, at regular intervals in later cycles, and whenever clinically indicated.

More frequent ECG and serum electrolyte monitoring may be required based on a patient's individual risk factors, and in the event of QTc prolongation and/or serum electrolyte imbalance (see <u>7</u> <u>WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests</u> and <u>4 DOSAGE AND</u> <u>ADMINISTRATION</u> sections).

KISQALI should be avoided in combination with other medicinal products known to prolong the QTc interval and/or strong CYP3A inhibitors as this may lead to further prolongation of the QTcF interval (see <u>4 DOSAGE AND ADMINISTRATION</u>, <u>9 DRUG INTERACTIONS</u> and <u>10 CLINICAL PHARMACOLOGY</u> sections). Use caution when KISQALI is in combination with agents known to cause bradycardia (e.g., beta-blockers, non-dyhydropyridine calcium channel blockers, clonidine, and digoxin.)

Based on the observed QT prolongation during treatment, KISQALI may require dose interruption, reduction or discontinuation as described in Table 4: Dose Modification and Management-QT prolongation (see <u>4 DOSAGE AND ADMINISTRATION</u>, <u>8 ADVERSE REACTIONS</u> and <u>10 CLINICAL</u> <u>PHARMACOLOGY</u> sections).

When drugs that prolong the QTc interval are prescribed, health professionals should counsel their patients concerning the nature and implications of the ECG changes, underlying diseases and disorders that are considered to represent risk factors, demonstrated and predicted drug-drug interactions,

symptoms suggestive of arrhythmia, risk management strategies, and other information relevant to the use of the drug. Patients should be advised to contact their health professional immediately to report any new chest pain or discomfort, changes in heartbeat, palpitations, dizziness, lightheadedness, fainting, or changes in or new use of other medications.

#### Increased QTc Prolongation with Concomitant Use of Tamoxifen

KISQALI is not indicated for use in combination with tamoxifen and combined treatment is not recommended (see <u>10 PHARMACOLOGY</u>, <u>Cardiac Electrophysiology</u>). In E2301 (MONALEESA-7), the observed mean QTcF interval increase from baseline in the tamoxifen 20 mg/day plus placebo subgroup was approximately 14-18 msec at steady-state on C3/D15 (i.e., Day 71) compared with approximately 2-3 msec in the NSAI plus placebo population, suggesting that tamoxifen had a QTcF interval prolongation effect which contributed to the QTcF interval prolongation observed in the KISQALI plus tamoxifen group (see 10 CLINICAL PHARMACOLOGY, Cardiac Electrophysiology). In the placebo arm, an increase of >60 msec from baseline occurred in 6/90 (6.7%) of the patients receiving tamoxifen 20 mg/day, and in no patients (0/245) receiving an NSAI. An increase of >60 msec from baseline in the QTcF interval was observed in 14/87 (16.1%) of patients receiving KISQALI plus tamoxifen and in 18/245 (7.3%) of patients receiving KISQALI plus an NSAI.

Tamoxifen exposure ( $C_{max}$  and  $AUC_{0-24h}$ ) was increased approximately 2-fold following co-administration of ribociclib and tamoxifen (see <u>9 DRUG INTERACTIONS</u>).]

#### Driving and operating machinery

Fatigue and syncope have been reported with the use of KISQALI. Patients should exercise caution when driving or operating machinery while taking KISQALI.

#### Hematologic

#### Neutropenia

In the pooled phase III clinical studies, neutropenia was the most frequently reported adverse drug reaction (75.4%) and a Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 decrease in neutrophil counts (based on laboratory findings) was reported in 62.0% of patients receiving KISQALI plus any combination.

Among the patients who had Grade 2, 3 or 4 neutropenia in the pooled phase III clinical studies, the median time to Grade 2, 3 or 4 neutropenia was 17 days The median time to resolution of Grade  $\geq$ 3 (to normalization or Grade <3) was 12 days in the KISQALI plus any combination treatment group. Severity of neutropenia is concentration dependent. Febrile neutropenia was reported in 1.7% of patients exposed to KISQALI in the phase III clinical studies. Physicians should inform patients to promptly report any fever (see <u>8 ADVERSE DRUG REACTIONS</u> section).

A complete blood count (CBC) should be performed before initiating therapy with KISQALI. CBC should be monitored every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles and as clinically indicated.

Based on the severity of the neutropenia, KISQALI may require dose interruption, reduction or discontinuation as described in Table 2: Dose Modification and Management for Neutropenia (see <u>4</u> <u>DOSAGE AND ADMINISTRATION</u> section).

#### **Other Hematologic Parameters**

Decreases in lymphocytes, leukocytes, hemoglobin and platelets were observed in patients treated with KISQALI. Grade 3 or 4 leukopenia was reported in 15.5% of patients in the KISQALI arm in the pooled phase III studies (see <u>8 ADVERSE REACTIONS</u>).

In clinical trials with KISQALI, anemia and leukopenia were usually managed with temporary KISQALI interruption and/or dose reduction. Monitor complete blood count prior to the start of KISQALI therapy, every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated (see <u>7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests</u> and <u>4</u> <u>DOSAGE AND ADMINISTRATION</u> sections).

## Hepatic/Biliary/Pancreatic

#### Hepatobiliary toxicity

In the pooled phase III clinical studies, hepatobiliary toxicity events occurred in a higher proportion of patients in the KISQALI plus any combination arms vs the placebo plus any combination arms (27.3% vs 19.6%, respectively) with more Grade 3/4 AEs reported in patients treated with KISQALI plus any combination (13.2% vs. 6.1%, respectively. Dose interruptions and/or adjustments due to hepatotobiliary toxicity events were reported in 12.3% of KISQALI -treated patients, primarily due to ALT increased (7.9%) and/or AST increased (7.3%). Discontinuation of treatment with KISQALI due to abnormal liver function tests and hepatotoxicity occurred in 2.4% and 0.3% of patients respectively.

Of the six patients in KISQALI plus fulvestrant group who met biochemical criteria of Hy's Law, two were confirmed. KISQALI was discontinued in both of these cases and these patients subsequently recovered after discontinuation.

In the pooled phase III clinical studies, increases in transaminases were observed. Grade 3 or 4 increases in alanine aminotransferase (ALT, 11.2% vs. 1.7%) and aspartate aminotransferase (AST, 7.8% vs. 2.1%) were reported in the KISQALI plus any combination and placebo plus any combination arms respectively. Grade 4 increases in ALT (2.0% vs. 0.2%) and AST (1.1% vs. 0.1%) were reported in the KISQALI plus any combination arms respectively.

Concurrent elevations of ALT or AST greater than three times the upper limit of normal (ULN) and of total bilirubin greater than two times the ULN, with normal ALP levels, and in the absence of cholestasis (consistent with the definition of drug-induced liver injury) occurred in 6 (0.6%) patients (4 patients in Study A2301) whose levels recovered to normal within 154 days; and 2 patients in Study F2301, whose levels recovered to normal within 154 days, respectively, after discontinuation of KISQALI. There were no such cases reported in Study E2301.

In the pooled phase III clinical studies, 70.9% (90/127) of Grade 3 or 4 ALT or AST elevation events occurred within the first 6 months of treatment (see <u>8 ADVERSE REACTIONS</u> section). The majority of increases in ALT and AST were reported without concurrent elevations of bilirubin. Among the patients who had Grade 3 or 4 ALT/AST elevation, the median time-to-onset was 92 days for the KISQALI plus any combination treatment group. The median time to resolution (to normalization or Grade  $\leq 2$ ) was 21 days in the KISQALI plus any combination treatment group.

Liver function tests (LFTs) should be performed before initiating therapy with KISQALI. The LFTs should be monitored every 2 weeks for the first 2 cycles at the beginning of each of the subsequent 4 cycles, and as clinically indicated. In the event of Grade  $\geq$  2 LFT abnormality, more frequent monitoring is required (see <u>7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests</u> and <u>4 DOSAGE AND ADMINISTRATION</u> sections).

Based on the severity of the transaminase elevations, KISQALI may require dose interruption,

reduction, or discontinuation as described in Table 3: Dose modification and management – Hepatobiliary toxicity (see <u>4 DOSAGE AND ADMINISTRATION</u> section). Recommendations for patients who have elevated AST/ALT Grade  $\geq$ 3 at baseline have not been established.

#### **Monitoring and Laboratory Tests**

- **Complete blood count (CBC):** CBC should be performed before initiating therapy with KISQALI. CBC should be monitored every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles and as clinically indicated.
- Liver function test (LFT): LFT should be performed before initiating therapy with KISQALI. LFT should be monitored every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated (for example, repeating liver enzyme and serum bilirubin twice weekly may be required in case of liver enzyme or bilirubin increase requiring dose interruption).
- *Electrocardiography (ECG):* Assess ECGs prior to initiating treatment, during Cycle 1 at approximately Day 14, at the beginning of Cycle 2, at regular intervals thereafter during steady-state treatment (at approximately Day 14 of the cycle), and whenever clinically indicated. Treatment with KISQALI should be initiated only in patients with QTcF value less than 450 msec. QTc prolongation is expected to be maximal during steady-state treatment between days 8 and 21 of the 28-day cycle. More frequent ECG monitoring is recommended whenever clinically indicated, for example in case of QTc prolongation during treatment or if the patient has underlying risk factors for Torsade de Pointes or is receiving concomitant treatment with drugs that prolong the QTc interval. Repeat ECGs should be performed if there are any symptoms that may be related to QT prolongation (e.g. palpitations or syncope), or in the event of electrolyte imbalances.
- **Electrolytes:** Monitoring of serum electrolytes (including potassium, calcium, phosphorus and magnesium) should be performed prior to initiation of treatment, at regular intervals during steady-state treatment in later cycles, and whenever clinically indicated. Any abnormality should be corrected before the initiation or continuation of KISQALI therapy.

## **Reproductive Health: Female and Male Potential**

Based on animal studies and the mechanism of action of ribociclib, KISQALI can cause fetal harm when administered to a pregnant woman. Women of reproductive potential should be advised to use effective contraception during therapy with KISQALI and for at least 21 days after the last dose (see <u>16 NON-CLINICAL TOXICOLOGY</u> section). There are no clinical data available regarding the effects of KISQALI on fertility, based on animal studies.

## • Male Fertility

KISQALI may impair fertility in males of reproductive potential (see <u>16 NON-CLINICAL TOXICOLOGY</u> section).

## Respiratory

## Interstitial Lung Disease (ILD)/Pneumonitis

Severe, life-threatening, or fatal ILD and/or pneumonitis can occur in patient treated with KISQALI and other CDK4/6 inhibitors. Across clinical trials (MONALEESA-2 (A2301), MONALEESA-7 (E2301-NSAI) and MONALEESA-3 (F2301)) 1.6% of KISQALI-treated patients had ILD/pneumonitis of any grade, 0.3% had Grade 3 or 4, and 0.1% had a fatal outcome. Additional cases of ILD/pneumonitis have been observed

with KISQALI in the post-marketing setting (see 8.5 ADVERSE DRUG REACTIONS, Post-Marketing Adverse Events).

Based on the severity of the ILD/pneumonitis patients may require treatment interruption, dose reduction or permanent discontinuation as described in Table 5 (see <u>4 DOSAGE AND</u> <u>ADMINISTRATION</u>).

Patients should be monitored for pulmonary symptoms indicative of ILD/pneumonitis. In patients who develop grade 1 ILD/pneumonitis, no dose adjustment is required. Appropriate medical therapy and monitoring should be initiated as clinically indicated. In patients who developed grade 2 ILD/pneumonitis, the treatment with KISQALI should be interrupted until recovery to grade ≤1, and then KISQALI can be resumed at the next lower dose level. For Grade 3 or 4 ILD/pneumonitis KISQALI should be permanently discontinued (see <u>4 DOSAGE AND ADMINISTRATION</u>).

## Skin

#### Severe cutaneous reactions

Toxic epidermal necrolysis (TEN) has been reported with Kisqali treatment. If signs and symptoms suggestive of severe cutaneous reactions (e.g., progressive widespread skin rash often with blisters or mucosal lesions) appear, KISQALI should be immediately and permanently discontinued.

## Thromboembolic events

In the pooled phase III clinical studies, thromboembolic events occurred in 37 patients (3.5%) in the KISQALI plus any combination, compared with 19 (2.3%) in the placebo plus any combination. Pulmonary embolism was reported in 14 patients (1.3%) receiving KISQALI plus any combination and 10 patients (1.2%) receiving placebo plus any combination.

Patients at risk of thromboembolic events should be closely monitored while receiving KISQALI.

## 7.1 Special Populations

## 7.1.1 Pregnant Women

There are no adequate and well-controlled studies using KISQALI in pregnant women. Ribociclib showed fetotoxicity and teratogenicity at doses which did not show maternal toxicity in rats and rabbits (see <u>16 NON-CLINICAL TOXICOLOGY</u> section). It is possible that KISQALI can cause fetal harm when administered to a pregnant woman.

Female patients of reproductive potential should have a pregnancy test prior to initiation of treatment with KISQALI. The patient should be advised of the risk to a fetus, if KISQALI is used during pregnancy or if the patient becomes pregnant while taking KISQALI.

## 7.1.2 Breast-feeding

Ribociclib and its metabolites readily passed into the milk of lactating rats. It is not known if ribociclib is excreted in human milk. There are no data on the effects of ribociclib on the breastfed child or the effects of ribociclib on milk production.

Because of the potential for serious adverse reactions in nursing infants from KISQALI, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the

importance of the drug to the mother. It is recommended that women taking KISQALI should not breastfeed for at least 21 days after the last dose (see <u>16 NON-CLINICAL TOXICOLOGY</u> section).

## 7.1.3 Pediatrics

**Pediatrics (≤ 18 years of age):** There are limited data in pediatric patients and the safety and efficacy of KISQALI in this population have not been established; therefore Health Canada has not authorized an indication for pediatric use.

## 7.1.4 Geriatrics

**Geriatrics (≥ 65 years of age):** Of 334 patients who received KISQALI plus letrozole in the phase III study A2301, 150 patients (45%) were ≥65 years of age. Of 483 patients who received KISQALI plus fulvestrant in the phase III study F2301, 226 patients (47%) were ≥65 years of age and 65 patients (13.5%) were ≥75 years of age. No major differences in safety of KISQALI were observed between these patients and patients <65 years of age (see <u>4 DOSAGE AND ADMINISTRATION</u> section).

## 7.1.5 Hepatic Impairment:

Based on a pharmacokinetic trial in subjects with hepatic impairment (Child-Pugh Class), mild hepatic impairment (Child-Pugh Class A) had no effect on the exposure of ribociclib; no initial dose reduction is required for patients with mild hepatic impairment at baseline.

In the Phase III study, the efficacy and safety of KISQALI have not been studied in patients with moderate or severe hepatic impairment [defined as breast cancer patients with ALT or AST  $\ge$  5 x ULN or total serum bilirubin  $\ge$  ULN (with the exception of documented Gilbert's Syndrome), as these patients were excluded according to the protocol eligibility criterion]. Treatment decision should be based on individual benefit/risk assessment for patients with moderate and severe hepatic impairment. If treatment is required, the starting dose should be reduced to 400 mg and patients should be closely monitored (see <u>10 CLINICAL PHARMACOLOGY</u> and <u>4 DOSE AND ADMINISTRATION</u> sections).

## 7.1.6 Renal Impairment:

KISQALI has not been studied in breast cancer patients with severe renal impairment.

Based on population pharmacokinetic analysis, and data from cancer patients in clinical trials; no starting dose adjustment is necessary for patients with mild or moderately impaired renal function and patients should be closely monitored (see <u>10 CLINICAL PHARMACOLOGY</u> and <u>4 DOSE AND</u> <u>ADMINISTRATION</u> sections).

Based on a renal impairment study in non-cancer subjects with severe renal impairment and normal renal function, a starting dose of 200 mg is recommended for patients with severe renal impairment.

Caution should be used in patients with severe renal impairment with close monitoring for signs of toxicity. Treatment decision should be made based on individual benefit/risk assessment for patients with severe renal impairment. (see <u>10 CLINICAL PHARMACOLOGY</u>).

## 8 ADVERSE REACTIONS

## 8.1 Adverse Reaction Overview

The overall safety evaluation of KISQALI is based on the pooled data set of 1065 patients who received

KISQALI in combination with endocrine therapy (N=582 in combination with non-steroidal aromatase inhibitor (NSAI), and N=483 in combination with fulvestrant), in double blind, placebo-controlled phase III clinical studies (MONALEESA-2, MONALEESA-7-NSAI population, MONALEESA-3) in HR-positive, HER2-negative advanced or metastatic breast cancer.

The median duration of exposure to study treatment across the pooled phase III studies dataset was 19.2 months with 61.7% patients exposed for >12 months.

The most common adverse drug reactions (ADRs) across the pooled phase III studies (reported at a frequency of  $\geq$ 20% and exceeding the frequency for placebo) were neutropenia, infections/infestations, nausea, fatigue, diarrhea, leukopenia, vomiting, headache, constipation, alopecia, cough, rash, back pain, anemia, and abnormal liver function tests.

The most common Grade 3/4 ADRs in the pooled data (reported at a frequency of  $\geq$ 2% and exceeding the frequency for placebo) were neutropenia, leukopenia, abnormal liver function tests, lymphopenia, infections/infestations, back pain, anemia, fatigue, dry mouth, oropharyngeal pain, hypophosphatemia and vomiting. Dose reductions of KISQALI or placebo due to adverse events (AEs), regardless of causality occurred in 39.5% of patients receiving KISQALI in phase III clinical studies regardless of the combination and in 4.3% of patients receiving placebo. No dose reduction was allowed for NSAI or fulvestrant in the phase III studies. Permanent discontinuation of KISQALI or placebo due to AEs, regardless of causality occurred in 17.2% n KISQALI plus any combination versus 5.1% in placebo plus any combination; The most common AEs leading to permanent discontinuation of KISQALI with any combination partner were ALT increased (4.5%), AST increased (2.5%) and vomiting (1.1%). Adverse events leading to treatment permanent discontinuations reported in 8.7% of patients receiving Kisqali plus any combination and in 3.1% of patients receiving placebo plus any combination.

In addition, the safety of KISQALI in combination with letrozole was evaluated in men (n=39) in an open-label, multicenter clinical study (COMPLEEMENT-1) for the treatment of patients with HR-positive, HER2-negative, advanced breast cancer who received no prior hormonal therapy for advanced disease. The median duration of exposure to KISQALI was 20.8 months (range: 0.5 to 30.6 months).

Adverse reactions occurring in men treated with KISQALI plus letrozole and goserelin were similar to those occurring in women treated with KISQALI plus endocrine therapy.

The most common Grade  $\geq$  3 AEs, regardless of causality, leading to permanent discontinuation of KISQALI with letrozole and goserelin were ALT increased (2.6%) and peripheral oedema (2.6%).

In the pooled studies, ILD was reported in 3 patients (0.3%) and pneumonitis was reported in 6 patients (0.6%) in the ribociclib arm (N=1065). In the placebo arm, ILD was not reported, and pneumonitis was reported in 3 patients (0.4%) (N= 818).

In the pooled analysis of three phase III studies, on-treatment deaths were reported in 22 patients (2.1%) treated with KISQALI plus any combination versus 16 patients (2.0%) treated with placebo plus any combination treatment. Excluding the most frequent causes of death, disease progression, 3 treatment-related causes of death were reported in patients treated with KISQALI plus any combination treatment. Causes of death were acute respiratory distress syndrome 2 (0.2%), acute respiratory failure 1 (0.1%), and sudden death (in a patient who had Grade 3 hypokalaemia and Grade 2 QT prolongation that improved to Grade 1 on the same day, both reported 10 days before the event) 1 (0.1%).

In Study F2301, on-treatment deaths, regardless of causality, were reported in 7 patients (1.4%) due to the underlying malignancy and 6 patients (1.2%) due to other causes while on treatment with KISQALI plus fulvestrant. Causes of death included one pulmonary embolism, one acute respiratory distress

syndrome, one cardiac failure, one pneumonia, one hemorrhagic shock, and one ventricular arrhythmia. Seven patients (2.9%) died due to the underlying malignancy and 1 patient (0.4%) died due to pulmonary embolism while on placebo plus fulvestrant.

## QT interval prolongation

In the phase III clinical studies, 9.3% of patients in the KISQALI plus any combination and 3.5% in the placebo plus any combination had at least one event of QT interval prolongation (including ECG QT interval prolonged, syncope). Dose interruptions and/or adjustments were reported in 2.9% of KISQALI-treated patients due to electrocardiogram QT interval prolonged and syncope.

A central analysis of ECG data (average of triplicate) showed 55 patients (5.2%) and 12 patients (1.5%) with at least one post-baseline QTcF interval >480 m sec for the KISQALI treatment arm and the placebo arms respectively. In study A2301, ECG assessments during steady-state treatment were collected only on Cycle 1, Day 15. Among the patients who had QTcF prolongation of >480 msecs, the median time to onset was 15 days regardless of the combination and these changes were reversible with dose interruption and/or dose adjustment (see <u>4 DOSAGE AND ADMINISTRATION</u>, <u>7 WARNINGS AND PRECAUTIONS</u> and <u>10 CLINICAL PHARMACOLOGY</u> sections).

## Neutropenia

Neutropenia was most frequently reported by laboratory findings in the phase III studies. Based on its severity, neutropenia was managed by laboratory monitoring, dose interruption and/or dose modification. Treatment discontinuation due to neutropenia occurred in 8 of 1065 (0.8%) patients receiving KISQALI plus any combination partner. Dose interruptions due to neutropenia occurred in 434 of 1065 (40.8%) patients and led to dose reductions in 196 of 1065 (18.4%) of the patients receiving KISQALI plus letrozole (see <u>4 DOSAGE AND ADMINISTRATION</u> and <u>7 WARNINGS AND PRECAUTIONS</u> sections).

## 8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

ADRs from the phase III clinical studies (Table 7, 8 and 9) are listed by MedDRA system organ class (MedDRA version 18.1). Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.

# Table 7 Adverse drug reactions observed in $\ge$ 10% and $\ge$ 2% higher than Placebo Arm in the phase III clinical study A2301

System Organ Class	KISO	ALI plus Letr N=334			ozole	
	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4
Adverse drug reactions	%	%	%	%	%	%
Blood and lymphatic	system diso	orders				
Neutropenia	77	54	10	6	1	0
Leukopenia	35	21	1	5	<1	0
Anemia	24	3	<1	8	2	0
Lymphopenia	13	7	1	3	1	0
Thrombocytopenia <sup>1</sup>	11	<1	0	<1	<1	0
Eye Disorders						
Lacrimation increase	12	0	0	2	0	0
Gastrointestinal diso	orders					
Nausea	55	3	0	32	<1	0
Diarrhea	41	2	0	26	<1	0
Vomiting	35	4	0	19	<1	0
Constipation	30	1	0	22	0	0
Abdominal pain	21	1	0	14	<1	0
Stomatitis	16	<1	0	7	0	0
Dysgeusia	10	<1	0	7	0	0

	KISO	ALI plus Letr N=334	rozole	Placebo plus Letrozole N=330			
System Organ Class	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4	
Adverse drug reactions	%	%	%	%	%	%	
Dyspepsia	11	<1	0	8	0	0	
General disorders an	d administra	ation site cor	nditions				
Fatigue	43	3	<1	35	<1	0	
Peripheral edema	19	<1	0	13	0	0	
Pyrexia	15	<1	0	7	0	0	
Asthenia	14	2	0	15	1	0	
Dry mouth	14	<1	0	11	<1	0	
Infections							
Respiratory tract infections <sup>2</sup>	39	2	<1	31	<1	0	
Urinary tract infections <sup>3</sup>	19	1	0	11	0	0	
Investigations							
Abnormal liver function tests <sup>4</sup>	23	10	2	9	2	0	
Metabolism and nut	rition disord	ers					
Decreased appetite	22	1	0	18	<1	0	
Blood creatinine increase	11	<1	0	3	0	0	
Musculoskeletal and	connective	tissue disord	lers				

	KISO	ALI plus Letr N=334	ozole	Placebo plus Letrozole N=330			
System Organ Class	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4	
Adverse drug reactions	%	%	%	%	%	%	
Back pain	27	3	0	23	1	0	
Nervous system diso	rders						
Headache	29	<1	0	23	<1	0	
Insomnia	17	0	0	14	0	0	
Respiratory, thoracio	and medias	tinal disorde	ers				
Dyspnea	16	2	0	13	<1	0	
Skin and subcutaneo	us tissue dis	orders					
Alopecia	35	0	0	17	0	0	
Rash⁵	24	1	0	11	<1	0	
Pruritus	18	<1	0	8	0	0	
Dry skin	10	0	0	4	0	0	

<sup>1</sup>Thrombocytopenia: platelet count decreased (3.3% with no Grade 3/4)

<sup>2</sup> Respiratory tract infections: upper respiratory tract infections, nasopharyngitis, bronchitis (8%), sinusitis (6%), pneumonia (5%), rhinitis (4%), respiratory tract infection (2%), pharyngitis (2%), lower respiratory tract infection (2%), laryngitis (1%), viral upper respiratory tract infection (1%), acute sinusitis (<1%), atypical pneumonia (<1%), viral sinusitis (<1%).

<sup>3</sup> Urinary tract infections: urinary tract infection, cystitis (4%), escherichia urinary tract infection (<1%).

<sup>4</sup>Abnormal liver function tests: ALT increased, AST increased, blood bilirubin increased (2%).

<sup>5</sup>Rash: rash, rash maculopapular (4%), rash pruritic (1%).

## Table 8 Adverse Drug Reactions Observed in $\ge$ 10% and $\ge$ 2% higher than Placebo Arm in the phase III clinical Study E2301 (NSAI)

KISQALI plus NSAI plus goserelin

Placebo plus NSAI plus goserelin

System Organ Class	-					7
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4
Adverse drug reactions	%	%	%	%	%	%
Blood and lymphatic system	n disorders					
Neutropenia	80	57	12	10	4	1
Leukopenia	34	15	<1	4	1	0
Anemia	20	4	0	9	2	0
Lymphopenia	13	5	<1	3	1	<1
Thrombocytopenia <sup>1</sup>	10	0	<1	2	0	<1
Gastrointestinal disorders	·					
Nausea	34	0	0	25	0	0
Diarrhea	23	2	0	21	0	0
Abdominal Pain	19	1	0	16	<1	0
Constipation	18	0	0	14	0	0
Stomatitis	14	0	0	9	<1	0
General disorders and admi	nistration site o	onditions			·	
Pyrexia	18	1	0	8	<1	0
Pain in extremity	16	0	0	10	1	0
Asthenia	15	1	0	11	0	0
Peripheral edema	11	0	0	8	0	0
Oropharyngeal pain	10	0	0	4	0	0
Infections and Infestations						
Infections <sup>2</sup>	43	2	0	32	<1	0
Investigations		•	•			
Abnormal liver function	21	7	0	15	3	0
tests <sup>3</sup>	21	/	0	12	3	0
Electrocardiogram QT	10	1	0	2	0	0
prolonged	10	L	U	Z	0	U
Musculoskeletal and connect	ctive tissue diso	orders				
Arthralgia	43	1	0	38	1	0
Back pain	24	1	0	22	2	0
Nervous system disorders						
Headache	29	0	0	26	<1	0
Respiratory, thoracic and m	ediastinal disor	ders				
Cough	20	0	0	11	0	0
Skin and subcutaneous tissu	e disorders					
Alopecia	21	0	0	14	0	0
Rash	20	<1	0	10	0	0
Pruritus	12	0	0	6	0	0
Grading according to CTCAE 4.C <sup>1</sup> Thrombocytopenia: thromboc <sup>2</sup> Infections: urinary tract infect <sup>3</sup> Abnormal liver function tests:	cytopenia (5%), pl ions; respiratory t	latelet count tract infection	decreased (4 ns; gastroent	1%). eritis (4%).	d (2%).	

Table 9 Adverse Drug Reactions Observed in  $\ge$  10% and  $\ge$  2% higher than Placebo Arm in phase III clinical Study F2301

	KISQ	ALI + fulves	trant	Placebo + fulvestrant			
System Organ Class		N = 483		N = 241			
	All	Grade 3	Grade 4	All	Grade 3	Grade 4	
	Grades			Grades			
Adverse drug reactions	%	%	%	%	%	%	
Blood and lymphatic system disc	orders		_		-		
Neutropenia	72	50	8	4	1	0	
Leukopenia	31	15	<1	1	0	0	
Anemia	20	4	0	9	3	0	
Lymphopenia	10	5	<1	1	0	0	
Gastrointestinal disorders							
Nausea	47	2	0	31	1	0	
Diarrhea	33	1	0	22	1	0	
Vomiting	29	2	0	14	0	0	
Constipation	26	1	0	13	0	0	
Abdominal pain	19	2	0	15	1	0	
Stomatitis	12	1	0	5	0	0	
Dyspepsia	11	0	0	6	0	0	
General disorders and administr	ation site co	nditions			•		
Peripheral edema	17	0	0	9	0	0	
Asthenia	16	<1	0	13	<1	0	
Pyrexia	15	<1	0	7	0	0	
Infections and Infestations							
Infections <sup>1</sup>	48	6	0	35	3	0	
Investigations							
Abnormal liver function tests <sup>2</sup>	18	8	2	10	1	0	
Metabolism and nutrition disord	lers						
Decreased appetite	18	<1	0	13	0	0	
Nervous system disorders							
Headache	25	1	0	21	<1	0	
Dizziness	15	<1	0	8	0	0	
Respiratory, thoracic and medias	stinal disord	ers	•	•	•	•	
Cough	25	0	0	17	0	0	
Dyspnea	18	2	<1	14	2	0	
Skin and subcutaneous tissue dis	sorders						
Rash	26	1	0	9	0	0	
Pruritus	22	1	0	7	0	0	
Alopecia	20	0	0	5	0	0	
Grading according to CTCAE 4.03 (Co	mmon Termi	nology Criteri	a for Adverse	Events)	1	•	

Grading according to CTCAE 4.03 (Common Terminology Criteria for Adverse Events)

<sup>1</sup>Infections: urinary tract infections; respiratory tract infections; gastroenteritis; sepsis (1%). <sup>2</sup>Abnormal liver function tests: ALT increased, AST increased, blood bilirubin increased

#### 8.3 Less Common Clinical Trial Adverse Reactions

Other clinically significant adverse drug reactions in Study A2301 reported in < 10% of patients and with higher incidences reported in the KISKALI plus letrozole arm (all grades) are presented below:

Blood and lymphatic system disorders: febrile neutropenia (1%)

Eye disorders: dry eye (8%), blurred vision (5%), cataract (5%)

Cardiac disorders: syncope (4%)

**General disorders and administration site conditions:** nasal congestion (5%), rhinorrhoea (5%), osteoarthritis (4%), contusion (4%), gingival pain (3%), osteonecrosis of the jaw (3%), nail disorder (3%)

Hepatobiliary disorders: hepatotoxicity# (2%)

Investigations: weight decreased (9%), electrocardiogram QT prolonged (5%)

**Metabolism and nutrition disorders:** hypokalemia (8%), hypocalcemia (7%), hypophosphatemia (4%), dehydration (4%), hyponatremia (3%)

Nervous system disorders: vertigo (8%), fall (4%), sleep disorder (4%)

Respiratory, thoracic and mediastinal disorders: epistaxis (5%), pulmonary embolism (2%)

Skin and subcutaneous tissue disorders: erythema (7%), oral herpes (4%), vitiligo (3%)

<sup>#</sup>Hepatotoxicity: hepatic cytolysis, drug-induced liver injury, hepatotoxicity, hepatic failure (single non- fatal case), autoimmune hepatitis (single case).

Other clinically significant adverse drug reactions in Study E2301 reported in < 10% of patients and with higher incidences reported in the Kisqali plus NSAI arm (all grades) are presented below:

Blood and lymphatic system disorders: febrile neutropenia (3%)

Cardiac disorders: tachycardia (3%)

Eye disorders: lacrimation increased (5%), dry eye (4%), visual impairment (3%), eye irritation (2%)

Gastrointestinal disorders: dyspepsia (7%), gastroesophageal reflux disease (4%)

**General disorders and administration site conditions:** influenza-like illness (8%), nasal congestion (4%), rhinorrhea (4%), flank pain (3%), malaise (2%), dyspareunia (2%)

Infections and Infestations: cellulitis (2%)

Metabolism and nutrition disorders: hypocalcemia (2%)

Musculoskeletal and connective tissue disorders: Non-cardiac chest pain (9%), muscle spasms (5%)

Skin and subcutaneous tissue disorders: dry skin (9%), vitiligo (5%), mouth ulceration (4%), aphthous ulcer (2%)

Other clinically significant adverse drug reactions in Study F2301 reported in < 10% of patients and with higher incidences reported in the Kisqali plus fulvestrant arm (all grades) are presented below:

Blood and lymphatic system disorders: thrombocytopenia (9%)

Cardiac disorders: syncope (2%)

Ear and labyrinth disorders: vertigo (7%)

Eye disorders: dry eye (6%), lacrimation increased (5%), conjunctivitis (3%)

Gastrointestinal disorders: dysgeusia (7%), dry mouth (5%), gastroesophageal reflux disease (5%)

**General disorders and administration site conditions:** neck pain (8%), hyperhidrosis (4%), chills (4%), pain in jaw (3%), nail disorder (3%), onychoclasis (3%)

Infections and Infestations: influenza (8%)

Investigations: electrocardiogram QT prolonged (6%)

**Metabolism and nutrition disorders:** blood creatinine increased (9%), hypocalcemia (5%), hypophosphatemia (4%)

Musculoskeletal and connective tissue disorders: Non-cardiac chest pain (5%), tremor (2%)

Nervous system disorders: depression (8%), memory impairment (3%)

## 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

#### **Clinical Trial Findings**

Clinically relevant abnormalities of routine hematological or biochemical laboratory values from the phase III studies, are presented in Tables 10, 11 and 12.

Laboratory abnormalities	KISQALI plus Letrozole N=334 %			Placebo plus Letrozole N=330 %			
	All grades	Grade 3 Grade 4			Grade 3	Grade 4	
	%	%	%	%	%	%	
Leukocyte count decreased	95	37	3	34	1	<1	
Neutrophil count decreased	94	53	11	28	1	<1	

#### Table 10 Laboratory abnormalities observed in the phase III clinical study A2301

Laboratory abnormalities	KISQALI plus Letrozole N=334 %			Placebo plus Letrozole N=330 %			
	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4	
	%	%	%	%	%	%	
Hemoglobin decreased	63	5	0	33	2	0	
Alanine aminotransferase increased (ALT)	59	11	2	42	1	0	
Lymphocyte count decreased	58	16	2	26	4	1	
Aspartate aminotransferase increased (AST)	57	7	1	39	2	0	
Platelet count decreased	35	1	0	9	<1	<1	
Creatinine increased	27	1	<1	8	<1	0	
Potassium decreased	16	2	2	9	2	0	
Phosphorous decreased	15	6	0	6	1	0	
Bilirubin increased	7	2	<1	4	1	0	

Table 11 Laboratory Abnormalities Observed in  $\geq$  10% of Patients in the phase III clinical Study E2301

Laboratory abnormalities	KISQA	LI + NSAI + g	goserelin	Placebo + NSAI + goserelin			
	N = 248						
	All	Grade 3	Grade 4	All	Grade 3	Grade 4	
	Grades			Grades			
	%	%	%	%	%	%	
HEMATOLOGY							
Leukocyte count decreased	94	38	3	35	1	<1	
Neutrophil count decreased	93	57	12	32	4	1	
Hemoglobin decreased	85	3	0	56	1	0	
Lymphocyte count decreased	60	17	3	21	3	1	
Platelet count decreased	31	<1	1	11	<1	1	
CHEMISTRY							
Aspartate aminotransferase increased	48	7	0	41	1	<1	
Gamma-glutamyl transferase increased	46	7	2	44	9	1	
Alanine aminotransferase increased	45	8	<1	34	2	1	
Phosphorous decreased	17	2	0	15	<1	<1	
Potassium decreased	17	1	<1	15	1	<1	
Glucose serum decreased	15	<1	1	11	<1	<1	
Creatinine increased	12	0	<1	4	0	0	

Table 12	Laboratory Abnormalities Observed in ≥ 10% of Patients in the phase III clinical Study
F2301	

Laboratory abnormalities	QALI + fulve	ALI + fulvestrant P			Placebo + fulvestrant		
		N = 483		N = 241			
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4	
	%	%	%	%	%	%	
HEMATOLOGY							
Leukocyte count decreased	95	29	1	29	<1	0	
Neutrophil count decreased	93	49	8	23	1	0	
Lymphocyte count decreased	75	19	2	38	4	1	
Hemoglobin decreased	64	6	0	38	4	0	
Platelet count decreased	35	1	1	12	0	0	
CHEMISTRY							
Creatinine increased	68	1	<1	35	<1	0	

Laboratory abnormalities	KISQALI + fulvestrant			Placebo + fulvestrant			
		N = 483					
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4	
	%	%	%	%	%	%	
Gamma-glutamyl transferase increased	57	8	1	50	9	2	
Aspartate aminotransferase increased	56	6	2	47	3	0	
Alanine aminotransferase increased	50	9	3	39	2	0	
Glucose serum decreased	25	0	0	21	0	0	
Phosphorous decreased	21	5	0	9	1	0	
Albumin decreased	12	0	0	9	0	0	

## 8.5 Post-Market Adverse Reactions

The following ADRs are derived from post-marketing experience with KISQALI via spontaneous case reports and literature cases. As these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known.

## Adverse drug reactions derived from spontaneous reports and literature (frequency not known)

Respiratory, thoracic and mediastinal disorders						
Interstitial lung disease (ILD)/pneumonitis						
Skin and subcutaneous tissue	e disorders					
Toxic epidermal necrolysis (TEN)						

## 9 DRUG INTERACTIONS

## 9.2 Drug Interactions Overview

Ribociclib is primarily metabolized by CYP3A and is a time-dependent inhibitor of CYP3A in vitro. Therefore, medicinal products which can influence CYP3A enzyme activity may alter the pharmacokinetics of ribociclib and ribociclib can affect the pharmacokinetics of co-administered CYP3A substrates.

## 9.4 Drug-Drug Interactions

Concomitant use of KISQALI and tamoxifen resulted in approximately a 2-fold increase in tamoxifen exposure and increased QTc prolongation. Avoid concomitant use of tamoxifen and drugs known to prolong QT interval, such as anti-arrhythmic medicines (see below).

Concomitant use of KISQALI and CYP3A inhibitors and inducers may respectively increase and decrease exposure to ribociclib. Co-administration of KISQALI and a strong CYP3A inhibitor or a strong CYP3A inducer should be avoided (see below).

Concomitant use of KISQALI and a CYP3A4 substrate may increase the exposure to the substrate. Coadministration of KISQALI and a CYP3A substrate with a narrow therapeutic index should be avoided; if avoidance is not possible, the dose of the substrate may need to be reduced (see below).

## Drugs that may increase ribociclib plasma concentrations

**CYP3A** *inhibitors:* Co-administration of a strong CYP3A4 inhibitor (ritonavir) increased ribociclib exposure in healthy subjects by 3.21-fold. Concomitant use of strong CYP3A inhibitors including, but not limited to, clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir, ritonavir, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, verapamil, and voriconazole should be avoided.

Alternative concomitant medications with a low potential to inhibit CYP3A should be considered and patients should be monitored for ADRs (see <u>4 DOSAGE AND ADMINISTRATION</u> and <u>7 WARNINGS AND</u> <u>PRECAUTIONS</u> sections).

If co-administration of KISQALI with a strong CYP3A inhibitor cannot be avoided, the KISQALI dose should be reduced to 200 mg. However, there are no clinical data with this dose adjustment (see <u>4</u> <u>DOSAGE AND ADMINISTRATION</u>). If the strong inhibitor is discontinued, the KISQALI dose should be resumed (after at least 5 elimination half-lives of the CYP3A inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor. Due to inter-patient variability (see <u>10 CLINICAL</u> <u>PHARMACOLOGY</u>), the recommended dose adjustments may not be optimal in all patients, therefore close monitoring for ADRs is recommended. In the event of KISQALI-related toxicity, dose interruption or reduction may be required until toxicity has resolved (see <u>4 DOSAGE AND ADMINISTRATION</u> section).

Patients should be instructed to avoid grapefruits or grapefruit juice, all of which are known to inhibit cytochrome CYP3A enzymes and may increase the exposure to ribociclib.

## Drugs that may decrease ribociclib plasma concentrations

**CYP3A inducers:** Co-administration of a strong CYP3A4 inducer (rifampin) decreased the plasma exposure of ribociclib in healthy subjects by 89%. Avoid concomitant use of strong CYP3A inducers, including, but not limited to, phenytoin, rifampin, carbamazepine and St John's Wort (*Hypericum perforatum*). An alternate concomitant medication with no or minimal potential to induce CYP3A should be considered (see <u>7 WARNINGS AND PRECAUTIONS</u> section).

## Drugs that may have their plasma concentrations altered by ribociclib

**CYP3A4 substrates:** Co-administration of midazolam (CYP3A4 substrate) with multiple doses of KISQALI (400 mg) increased the midazolam exposure by 280% (3.80-fold) in healthy subjects, compared with administration of midazolam alone. Simulations using physiologically-based PK (PBPK) models suggested that KISQALI given at the clinically relevant dose of 600 mg is expected to increase the midazolam AUC by 5.2-fold. Therefore co-administration of KISQALI with a CYP3A substrates with a narrow therapeutic index should be avoided. If avoidance is not possible, the dose of a sensitive CYP3A substrate with a narrow therapeutic index, including but not limited to alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus and tacrolimus, may need to be reduced.

**CYP1A2** substrates: Co-administration of caffeine (CYP1A2 substrate) with multiple doses of KISQALI (400 mg) increased caffeine exposure by 20% (1.20-fold) in healthy subjects, compared with administration of caffeine alone. At the clinically relevant dose of 600 mg, simulations using PBPK models predicted only weak inhibitory effects of ribociclib on CYP1A2 substrates (<2-fold increase in AUC).

#### Anti-arrhythmic medicines and other medicinal products that may prolong the QT interval

QTc interval prolongation has been reported in patients treated with KISQALI. The concomitant administration of KISQALI with other medicinal products known to prolong the QT interval or induce Torsade de Pointes should be avoided.

While the patient is using KISQALI, other QTc-prolonging drugs should be discontinued and alternative concomitant drugs that do not prolong the QTc interval should be chosen. When it is not feasible to avoid concomitant use of drugs known to prolong the QTc interval, obtain ECGs and electrolytes prior to the start of treatment, after initiation of any drug known to prolong QTc interval, and monitor periodically as clinically indicated during treatment.

Drugs that have been associated with QTc interval prolongation and/or Torsade de Pointes include, but are not limited to, the examples in the following list. Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QTc interval prolongation and/or Torsade de Pointes:

- Class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide)
- Class III antiarrhythmics (e.g., amiodarone, sotalol, ibutilide, dronedarone)
- Class 1C antiarrhythmics (e.g., flecainide, propafenone)
- antipsychotics (e.g., olanzapine, chlorpromazine, pimozide, haloperidol, droperidol, ziprasidone)
- antidepressants (e.g., fluoxetine, citalopram, venlafaxine, tricyclic/tetracyclic antidepressants [e.g., amitriptyline, imipramine, maprotiline])
- opioids (e.g., methadone)
- macrolide antibiotics and analogues (e.g., erythromycin, clarithromycin, azithromycin, tacrolimus)
- quinolone antibiotics (e.g., moxifloxacin, levofloxacin, ciprofloxacin)
- pentamidine
- antimalarials (e.g., quinine, chloroquine)
- azole antifungals (e.g., ketoconazole, fluconazole, voriconazole)
- domperidone
- anagrelide
- ivabradine
- 5-hydroxytryptamine (5-HT)3 receptor antagonists (e.g., ondansetron)
- tyrosine kinase inhibitors (e.g., sunitinib, nilotinib, ceritinib, vandetanib)
- arsenic trioxide
- histone deacetylase inhibitors (e.g., vorinostat)
- beta-2 adrenoceptor agonists (e.g., salmeterol, formoterol)

## Tamoxifen

KISQALI is not indicated for use in combination with tamoxifen and combined use is not recommended because of increased QTc prolongation (See <u>7 WARNINGS AND PRECAUTIONS</u>; <u>10 CLINICAL</u>

<u>PHARMACOLOGY</u>, <u>Cardiac Electrophysiology</u>). Data from a clinical trial in patients with breast cancer indicated that tamoxifen exposure ( $C_{max}$  and  $AUC_{0-24h}$ ) was increased approximately 2-fold following co-administration of ribociclib and tamoxifen.

## Drugs that affect electrolytes

Use of KISQALI with drugs that can decrease electrolyte levels should be avoided to the extent possible. Such drugs include, but are not limited to, the following: loop, thiazide, and related diuretics; laxatives and enemas; amphotericin B; high-dose corticosteroids; and proton pump inhibitors.

## Drugs that reduce heart rate

Avoid using KISQALI concomitantly with drugs that reduce heart rate (e.g., beta-blockers, digitialis glycosides, non-dihydropyridine calcium channel blockers, cholinesterase inhibitors, alpha2-adrenoceptor agonists, I<sub>f</sub> inhibitors and sphingosine-1 phosphate receptor modulators).

The above lists of potentially interacting drugs are not comprehensive. Current information sources should be consulted for newly approved drugs that prolong the QTc interval, inhibit CYP3A, or decrease electrolytes, as well as for older drugs for which these effects have recently been established.

## Gastric pH elevating medications

Ribociclib exhibited high solubility at or below pH 4.5 and in bio-relevant media (at pH 5.0 and 6.5). Coadministration of KISQALI with medicinal products that elevate the gastric pH was not evaluated in a clinical trial; however, altered ribociclib absorption was not observed in the population pharmacokinetic analysis nor in simulations using PBPK models.

## Effect of ribociclib on transporters

Ribociclib may inhibit Breast Cancer Resistance Protein (BCRP), Organic Cation Transporter 2 (OCT2), Multidrug and Toxic Compound Extrusion Protein-1 (MATE1), and human Bile Salt Export Pump (BSEP) at clinically relevant concentrations. Patients should be closely monitored when co-administered with ribociclib and substrates of these transporters.

*In vitro* evaluations indicated that ribociclib has a low potential to inhibit the activities of drug transporters P-glycoprotein (P-gp), Organic Anion Transporter 1 /3 (OAT1/3), Organic anion transporting polypeptides B1/B3 (OATP1B1/B3), Organic Cation Transporter 1 (OCT1), Multidrug and Toxic Compound Extrusion Protein 2K (MATE2K) and Multidrug resistance-associated protein 2 (MRP2) at clinically relevant concentrations.

## Effect of transporters on ribociclib

Based on *in vitro* data, P-gp and BCRP mediated transport are unlikely to affect the extent of oral absorption of ribociclib at therapeutic doses. Ribociclib is not a substrate for hepatic uptake transporters OATP1B1/1B3 or OCT-1 *in vitro*.

## Effect of ribociclib on CYP enzymes

*In vitro*, ribociclib did not inhibit CYP2E1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Ribociclib was a reversible inhibitor of CYP1A2 and CYP3A4/5 and a time-dependent inhibitor of

CYP3A4/5 at clinically relevant concentrations. No induction of CYP1A2, CYP2B6, CYP2C9 or CYP3A4 was observed *in vitro* at clinically relevant concentrations.

## Co-administration with Letrozole

Data from a clinical trial in patients with breast cancer and population PK analysis indicated no drug interaction between ribociclib and letrozole following co-administration of the drugs. (See Table 14, Pharmacokinetics).

**Co-administration with Exemestane:** Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and exemestane following coadministration of the drugs.

**Co-administration with Anastrozole:** Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and anastrozole following coadministration of the drugs.

**Co-administration with Fulvestrant:** Data from a clinical trial in patients with breast cancer indicated no clinically relevant effect of fulvestrant on ribociclib exposure following coadministration of the drugs.

**Co-administration with Goserelin:** No formal examination of the potential drug interaction with goserelin was done. The metabolism of goserelin is not CYP-mediated; rather hydrolysis of C-terminal amino acids is the major clearance mechanism. Based on the available information, goserelin is not expected to affect the metabolism of nor be affected by co-administered drugs. It is not clear if all molecules in this drug class would have no potential for drug interaction with ribociclib.

## 9.5 Drug-Food Interactions

KISQALI can be administered with or without food (see <u>4 DOSAGE AND ADMINISTRATION</u>).

Compared to the fasted state, oral administration of a single 600 mg dose of KISQALI film-coated tablet with a high-fat, high-calorie meal had no effect on the rate and extent of absorption of ribociclib ( $C_{max}$  GMR: 1.00; 90% CI: 0.898, 1.11; AUC<sub>inf</sub> GMR: 1.06; 90% CI: 1.01, 1.12 (see <u>10 CLINICAL PHARMACOLOGY</u> <u>section</u>).

KISQALI should not be administered with grapefruit, grapefruit juice, or grapefruit-containing products, all of which are known to inhibit cytochrome CYP3A enzymes and may increase the exposure to ribociclib.

## 9.6 Drug-Herb Interactions

Interactions with herbal products have not been established. St. John's wort (*Hypericum perforatum*) is an inducer of CYP3A4/5 that may decrease ribociclib plasma concentrations and should be avoided.

## 9.7 Drug-Laboratory Test Interactions

Interactions between KISQALI and laboratory tests have not been studied.

## **10 CLINICAL PHARMACOLOGY**

## **10.1** Mechanism of Action

Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways which lead to cell cycle progression

and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb) (see <u>16 NON-CLINICAL TOXICOLOGY, DETAILED</u> <u>PHARMACOLOGY, Pharmacodynamics</u> section).

*In vitro*, ribociclib decreased pRb phosphorylation leading to arrest in the G1 phase of the cell cycle and reduced cell proliferation in breast cancer cell lines. *In vivo*, treatment with single agent ribociclib led to tumor regressions which correlated with inhibition of pRb phosphorylation at well tolerated doses.

In *in vivo* studies using patient-derived estrogen positive breast cancer xenograft models, combination of ribociclib and antiestrogens (i.e. letrozole) resulted in superior inhibition of tumor growth compared to each drug alone. Additionally, *in vivo* antitumor activity of combination of ribociclib with fulvestrant was assessed in immune-deficient mice bearing human breast cancer xenografts. The combination of ribociclib and fulvestrant resulted in complete tumor growth inhibition.

#### **10.2** Pharmacodynamics

#### Cardiac electrophysiology

In the phase III clinical trial CLEE011A2301, the phase lb/II trial CLEE011X2107, and the phase III trial CLEE011E2301 in patients with HR+, HER2-negative breast cancer, ribociclib 600 mg was administered once daily for 21consecutive days followed by 7-day planned break (28-day cycle, 3 weeks on/1 week off). In CLEE011E2301 and CLEE011X2107, QTcF interval prolongation occurred that was maximal during steady-state treatment (day 8-21) (Table 13).

Study	Treatment	Cycle/Day	Time (h)	n	Mean Change from Baseline QTc (msec)	90% CI
CLEE011A2301	Ribociclib 600 mg	C1/D15	0	308	13.5	12.1, 14.9
	+ Letrozole 2.5 mg		2	277	19.6	18.0, 21.2
	Placebo +	C1/D15	0	313	1.7	0.5, 2.8
	Letrozole 2.5 mg		2	307	1.8	0.7, 3.0
CLEE011X2107	Ribociclib 600 mg	C1/D1	2	46	5.9	3.3, 8.6
	+ Letrozole 2.5		4	46	12.3	9.4, 15.3
	mg	C1/D8	0	46	10.6	7.4, 13.7
			4	46	19.3	15.5, 23.1
		C1/D15	0	46	11.5	7.4, 15.6
			2	42	23.0	19.1, 26.9
			4	42	21.5	17.1, 25.9
			8	43	20.3	16.5, 24.1
		C1/D21	0	43	14.3	11.1, 17.5
			2	39	21.7	17.6, 25.8
			4	40	24.6	18.9, 30.3

#### Table 13 Mean QTc change from baseline observed in Studies CLEE011A2301 and CLEE011X2107

In Study CLEE011E2301, the magnitude of the QTc prolongation effect was greater when KISQALI was administered in combination with tamoxifen than when KISQALI was administered in combination with NSAI. The QTc prolongation effects of tamoxifen and KISQALI appeared to be approximately additive. Because of the lengthy elimination half-life values of tamoxifen and its active metabolite, only the Cycle 3 data are expected to represent steady-state effects, with mean changes from baseline QTc of 27.6-32.6 msec in the KISQALI plus tamoxifen group and 13.7-17.6 msec in the placebo plus tamoxifen group KISQALI is not indicated for use in combination with tamoxifen and combined use is not recommended (see <u>9 DRUG INTERACTIONS-Tamoxifen</u>).

Ribociclib also appears to decrease heart rate. In study CLEE011X2107 (Arm 1; N=47), the mean change from baseline in heart rate was -5.5 bpm (90% CI: -7.3, -3.7, n=42) at 2 h post-dosing on C1D15 and -7.1 bpm (90% CI -8.8, -5.3) at 2 h post-dosing on C1D21.

In study CLEE011A2301 (N=334), the mean change from baseline in heart rate on C1D15 at 2 h postdose was -2.2 bpm (90% CI -3.2, -1.2; n=277) in the ribociclib plus letrozole arm and 1.7 bpm (90% CI: 0.8, 2.7, N=307) in the placebo plus letrozole arm.

Serial, triplicate ECGs were collected following a single dose and at steady-state to evaluate the effect of ribociclib on the QTc interval in patients with advanced cancer. A pharmacokinetic-pharmacodynamic analysis included a total of 997 patients treated with ribociclib at doses ranging from 50 to 1,200 mg. The analysis suggested that ribociclib causes concentration-dependent increases in the QTc interval. The estimated QTcF interval mean change from baseline for KISQALI 600 mg dose in combination with NSAI or fulvestrant was 22.00 msec (90% CI: 20.56, 23.44) and 23.7 msec (90% CI: 22.31, 25.08), respectively, at the geometric mean C<sub>max</sub> at steady-state compared to 34.7 msec (90% CI: 31.64, 37.78) in combination with tamoxifen (see <u>7 WARNING AND PRECAUTIONS</u>).

## 10.3 Pharmacokinetics

The pharmacokinetics of ribociclib were investigated in patients with advanced cancer following oral daily doses of 50 mg to 1,200 mg. Healthy subjects received single oral doses of 400 or 600 mg or repeated daily oral doses (8 days) of 400 mg.

	C <sub>max</sub> (ng/mL)	T <sub>max</sub> (h)	AUC <sub>0-24h</sub> (hr∙ng/mL)	T <sub>1/2</sub> ,acc (h)	CL/F (L/h)
Multiple	n=57	n=57	n=54	n=49	n=53
doses (C1, D18/21)	1820 (62.4)	2.40 (0.683, 7.82)	23800 (66.0)	32.0 (63.2)	25.5 (65.7)
600 mg (study X2101)					
Pooled <sup>1</sup>					

## Table 14 Summary of Ribociclib Pharmacokinetic Parameters

Multiple doses (C1 D21)	n=28 1720 (44.6)	n=28 2.11 (1.05, 7.67)	n=23 23290 (52.2)	n=18 30.4 (38.7)	n=20 26.5 (53.2)
600 mg (study X2107)					

C: cycle; D: day; n: number of patients with cancer with corresponding evaluable PK parameters; PK: pharmacokinetics.

Data are presented as geometric mean (CV% geo mean) for all parameters except for  $T_{max}$  which is presented as median (range)

<sup>1</sup> Pooled data from patients with cancer receiving intermittent schedule (3 weeks on 1 week off) and patients with cancer with continuous dosing (once daily for 28 days)

## Absorption

Following oral administration of ribociclib to patients with advanced solid tumors or lymphomas peak plasma levels (C<sub>max</sub>) of ribociclib were achieved between 1 and 4 hours (time to reach maximum concentration, T<sub>max</sub>). Ribociclib exhibited slightly over-proportional increases in exposure (C<sub>max</sub> and AUC) across the dose range tested (50 to 1,200 mg). Following repeated once daily dosing, steady-state was generally achieved after 8 days and ribociclib accumulated with a geometric mean accumulation ratio of 2.51 (range: 0.972 to 6.40).

Compared to the fasted state, oral administration of a single 600 mg dose of ribociclib film-coated tablet formulation with a high-fat, high-calorie meal had no effect on the rate and extent of absorption of ribociclib (C<sub>max</sub> GMR: 1.00; 90% CI: 0.898, 1.11; AUC<sub>inf</sub> GMR: 1.06; 90% CI: 1.01, 1.12) (see <u>9 DRUG</u> INTERACTIONS, Drug-Food Interaction section).

## Distribution:

Binding of ribociclib to human plasma proteins *in vitro* was approximately 70% and independent of concentration (10 to 10,000 ng/mL). Ribociclib was equally distributed between red blood cells and plasma with a mean *in vivo* blood-to-plasma ratio of 1.04. The apparent volume of distribution at steady-state (Vss/F) was 1,090 L based on the population pharmacokinetic analysis. In rats with intact blood brain barriers, there was relatively low brain penetration by ribociclib following oral administration and intracarotid injection.

## Metabolism:

*In vitro* and *in vivo* studies indicated that ribociclib undergoes extensive hepatic metabolism mainly via CYP3A4 in humans. Following oral administration of a single 600 mg dose of [<sup>14</sup>C]ribociclib to humans, the primary metabolic pathways for ribociclib involved oxidation [dealkylation, C and/or N-oxygenation, oxidation (-2H)] and combinations thereof. Phase II conjugates of ribociclib phase I metabolites involved N-acetylation, sulfation, cysteine conjugation, glycosylation and glucuronidation. Ribociclib was the major circulating drug-derived entity in plasma (43.5%). The major circulating metabolites included metabolite M13 (CCI284, N-hydroxylation), M4 (LEQ803, N-demethylation), and M1 (secondary glucuronide), each representing an estimated 9.39%, 8.60%, and 7.78% of total radioactivity, and 21.6%, 19.8%, and 17.9% of ribociclib exposure, respectively. The pharmacological effects of ribociclib are considered to be primarily due to parent drug, with negligible contribution from

circulating metabolites.

Ribociclib was extensively metabolized with the unchanged drug accounting for 17.3% and 12.1% of the dose in feces and urine, respectively. Metabolite LEQ803 was a significant metabolite in excreta and represented approximately 13.9% and 3.74% of the administered dose in feces and urine, respectively. Numerous other metabolites were detected in both feces and urine in minor amounts ( $\leq$  2.78% of the administered dose).

# Elimination

The geometric mean plasma effective half-life (based on accumulation ratio) was 32.0 hours (63% CV) and the geometric mean apparent oral clearance (CL/F) was 25.5 L/hr (66% CV) at steady-state at 600 mg in patients with advanced cancer. The geometric mean half-life ( $T_{1/2}$ ) of ribociclib ranged from 29.7 to 54.7 hours and the geometric mean CL/F of ribociclib ranged from 39.9 to 77.5 L/hr at 600 mg across studies in healthy subjects.

Ribociclib is eliminated mainly via the feces, with a small contribution from the renal route. In 6 healthy male subjects, following a single oral dose of [<sup>14</sup>C] ribociclib, 91.7% of the total administered radioactive dose was recovered within 22 days; feces was the major route of excretion (69.1%), with 22.6% of the dose recovered in the urine.

# **Special Populations and Conditions**

- **Pediatrics (< 18 years of age):** There are limited data in pediatric patients and the pharmacokinetics of ribociclib in this population has not been established.
- Geriatrics (≥ 65 years of age): Of 334 patients who received KISQALI plus letrozole in the phase III study A2301 (MONALEESA 2), 150 patients (45%) were ≥65 years of age. Of 483 patients who received KISQALI plus fulvestrant in the phase III study F2301 (MONALEESA 3), 226 patients (46.8%) were ≥65 years of age and 65 patients (13.5%) were ≥75 years of age No major differences in safety of KISQALI were observed between these patients and younger patients (see <u>4 DOSAGE AND ADMINISTRATION</u>).
- Effect of age, weight, gender and race: Population pharmacokinetic analysis showed that there are no clinically relevant effects of age, body weight, gender, or race on the systemic exposure of ribociclib that would require a dose adjustment. Two of 42 patients in the MONALEESA3 study (F2301), who had population pharmacokinetic simulated exposure and had age 65 or older as well as weight less than 59 kg, had Grade 3 or 4 pulmonary toxicity, in the context of progression of underlying malignancy.
- Hepatic Impairment: Based on a pharmacokinetic trial in subjects with hepatic impairment (Child-Pugh Class), mild hepatic impairment had no effect on the exposure of ribociclib. The mean exposure for ribociclib was increased less than 2-fold in subjects with moderate (geometric mean ratio [GMR]: 1.44 for C<sub>max</sub>; 1.28 for AUC<sub>inf</sub>) and severe (GMR: 1.32 for C<sub>max</sub>; 1.29 for AUC<sub>inf</sub>) hepatic impairment. Based on a population pharmacokinetic analysis that included 160 patients with normal hepatic function and 47 patients with mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin > 1 to ≤1.5 xULN and AST any value), mild hepatic impairment had no effect on the exposure of ribociclib.
- **Renal Impairment:** The effect of renal function on the pharmacokinetics of ribociclib was assessed in a renal impairment study in non-cancer subjects that included 14 subjects with normal renal function (Absolute Glomerular Filtration Rate (aGFR) ≥90 mL/min), 8 subjects with mild renal impairment (aGFR 60 to <90 mL/min), 6 subjects with moderate renal impairment

(aGFR 30 to <60 mL/min), 7 subjects with severe renal impairment (aGFR 15 to <30 mL/min), and 3 subjects with end stage renal disease (ESRD) (aGFR <15 mL/min) at single oral ribociclib dose of 400 mg.

The geometric means AUC<sub>inf</sub> (geometric %CV, n) for the following cohorts were: normal renal function 4100 ng\*hr/mL (53.2%, 14), mild renal impairment 6650 ng\*hr/mL (36.4%, 8), moderate renal impairment 7960 ng\*hr/mL (45.8%, 6), severe renal impairment 10900 ng\*hr/mL (38.1%, 7), and ESRD 13600 ng\*hr/mL (20.9%, 3). The C<sub>max</sub> (geometric %CV, n) values for the cohorts were: normal 234 ng/mL (58.5%, 14), mild 421 ng/mL (31.6%, 8), moderate 419 ng/mL (30.3%, 6), severe 538 ng/mL (43.3%, 7), and ESRD 593 ng/mL (11.3%, 3).

Based on a 2.67- and 2.30-fold increase in AUC<sub>inf</sub> and  $C_{max}$ , respectively, in subjects with severe renal impairment versus those with normal renal function, a starting dose of 200 mg ribociclib is recommended for patients with severe renal impairment (see <u>4 DOSAGE AND</u> <u>ADMINISTRATION</u>).

The effect of renal function on the pharmacokinetics of ribociclib was also assessed in cancer patients in clinical trials. Based on a population pharmacokinetic analysis that included 77 cancer patients with normal renal function [estimated glomerular filtration rate (eGFR)  $\geq$ 90 mL/min/1.73 m2], 76 patients with mild renal impairment (eGFR 60 to <90 mL/min/1.73 m2) and 35 patients with moderate renal impairment (eGFR 30 to <60 mL/min/1.73 m2), mild and moderate renal impairment had no clinically meaningful effect on the exposure of ribociclib. Similar findings were reported in a subgroup pharmacokinetic analysis based on three of the clinical trials in cancer patients treated with ribociclib 600 mg daily.

Both the population and subgroup PK analyses suggest that no starting dose adjustment is necessary in patients with mild or moderate renal impairment (see <u>4 DOSAGE AND</u> <u>ADMINISTRATION</u>).

# 11 STORAGE, STABILITY AND DISPOSAL

KISQALI should not be stored above 30°C.

Store in original package to protect from moisture.

# **12 SPECIAL HANDLING INSTRUCTIONS**

KISQALI must be kept out of the sight and reach of children.

### PART II: SCIENTIFIC INFORMATION

# **13 PHARMACEUTICAL INFORMATION**

#### Drug Substance

Proper name:

Chemical name:


ribociclib succinate

Butanedioic acid—7-cyclopentyl-*N*,*N*-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxamide (1/1)

Molecular formula and molecular mass:

Free base:  $C_{23}H_{30}N_8O$ Succinate salt:  $C_{23}H_{30}N_8O.C_4H_6O_4$ 552.64 g/mole (salt form) [free base: 434.55 g/mol]

Structural formula:



Physicochemical properties:

Physical Description:	Light yellow to yellowish brown crystalline powder
Solubility:	The solubility of ribociclib succinate drug substance is pH-dependent, with high solubility in acidic media and low solubility in neutral media.
	In acidic conditions, ribociclib succinate has a solubility > 2.4 mg/mL, but at pH 6.8 ribociclib freeform precipitates and the solubility decreases to 0.8 mg/mL. Ribociclib succinate is therefore considered to have low solubility according to the Biopharmaceutics Classification System (BCS).
pH:	The pH of a 1.0% m/V solution of ribociclib succinate drug substance in water is 5.19.
рКа:	The drug substance is an anhydrous succinate salt of ribociclib with pKa values of 5.3 and 8.5.
Partition Coefficient/Distributi	on Coefficient:

Distribution coefficients were measured for ribociclib succinate drug substance at different pH at 37 °C. The different values as function of the pH are reported below.

### Distribution coefficient:

Media pH (measured) Distribution	coefficient, D Log D (measured)
----------------------------------	---------------------------------

n-octanol / pH 1 (0.1 N HCl)	0.93	0.00290	-2.57
n-octanol / pH 5.5 (acetate buffer)	5.57	0.471	033
n-octanol / pH 7.5 (phosphate buffer)	7.45	71.9	1.85

Melting point:

Ribociclib succinate drug substance shows melting followed by decomposition at about 205 °C (by DSC).

# 14 CLINICAL TRIALS

### 14.1 Clinical Trials by Indication

In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

# Study CLEE011A2301 (MONALEESA-2)

# Table 15 - Summary of patient demographics for MONALEESA-2

Study #	Trial design	Dosage, route of administration and duration	Study subjects	Mean age (Range)	Gender
LEE011 A2301	A randomized, double-blind, placebo- controlled, multicenter phase III clinical study in the treatment of postmenopausal women with HR positive, HER2- negative, advanced breast cancer who received no prior therapy for advanced disease in combination with letrozole versus letrozole alone	Route of Administration : Oral Dosage: Ribociclib (600 mg once daily, on Days 1-21 of a 28- day cycle) plus letrozole (2.5 mg once daily in a 28- day cycle) Placebo (daily, on Days 1-21 of a 28-day cycle) plus letrozole (2.5 mg once daily in a 28-day cycle) Duration: Until disease progression, unacceptable toxicity, death, or study treatment discontinuation for any other reason. The median duration of exposure to the study treatment was similar in both treatment groups: 13.0 months in the ribociclib plus letrozole group (range: 0 to 23 months) and 12.4 months (range: 0 to 22	A total of 668 patients with advanced breast cancer Ribociclib plus Letrozole: 334 female patients Placebo plus Letrozole: 330 female patients 4 patients in Placebo plus Letrozole never treated	Ribociclib plus letrozole Mean= 61.4 (23-91)years of age Placebo plus letrozole All patients 61.9 (29-88) years of age	Post- menopausal women

months) in the placebo plus		
letrozole group		

Study CLEE011A2301 was a randomized, double-blind, placebo-controlled, multicenter phase III clinical study of KISQALI plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with HR positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease.

A total of 668 patients were randomized in a 1:1 ratio to receive either KISQALI 600 mg and letrozole (n= 334), or placebo and letrozole (n= 334), stratified according to the presence of liver and/or lung metastases. Demographics and baseline disease characteristics were balanced and comparable between study arms. KISQALI was given orally at a dose of 600 mg daily for 21 consecutive days followed by 7 days off treatment in combination with letrozole 2.5 mg once daily for 28 days. Patients were not allowed to cross over from placebo to KISQALI during the study or after disease progression.

Patients enrolled in this study had a median age of 62 years (range 23 to 91) with 44.2% 65 years of age and older, including 69 patients (10.3%) of age 75 years and older. The patients included were Caucasian (82.2%), Asian (7.6%), and Black (2.5%). All patients had an ECOG performance status of 0 or 1. A total of 46.6% of patients had received chemotherapy in the neoadjuvant or adjuvant setting and 51.3% had received antihormonal therapy in the neo/adjuvant setting prior to study entry. 34.1% of patients had de novo metastatic disease. 22.0% of patients had bone only disease and 58.8% of patients had visceral disease. Patients with CNS metastases documented at baseline were not permitted in this study.

# Primary analysis

The primary endpoint for the study was met at the planned interim analysis conducted after observing 80% of targeted progression-free survival (PFS) events using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), based on the investigator assessment in the full population (all randomized patients) and confirmed by a blinded independent central radiological assessment.

The efficacy results demonstrated a statistically significant improvement in PFS in patients receiving KISQALI plus letrozole compared to patients receiving placebo plus letrozole in the full analysis set (FAS) (HR = 0.556; 95% CI: 0.429, 0.720; one sided stratified log-rank test p-value = 0.00000329), with an estimated 44% reduction in risk of progression for patients treated with the combination of KISQALI plus letrozole. The median PFS was not reached in the KISQALI plus letrozole arm [95% CI: 19.3 - not reached (NR)] at the time of the primary analysis. The median PFS was 14.7 months (95% CI, 13.0, and

16.5) for the placebo plus letrozole arm.

Results were consistent across the subgroups of age, race, prior adjuvant or neo-adjuvant chemotherapy or hormonal therapies, liver and/or lung involvement, and bone only metastatic disease (Figure 2).

Updated Kaplan-Meier curve for PFS is provided in Figure 1.

The global health status/Quality of Life (QoL) showed no relevant difference between the KISQALI plus letrozole arm and the placebo plus letrozole control arm.

As shown in Table 16, an update of efficacy data resulted in a median PFS of 25.3 months (95% CI: 23.0, 30.3) for ribociclib plus letrozole treated patients and 16.0 months (95% CI: 13.4, 18.2) for patients receiving placebo plus letrozole; 54.7% of patients receiving ribociclib plus letrozole were estimated to be disease progression free at 24 months compared with 35.9% in the placebo plus letrozole arm.


Table 16 Efficacy Results Based on Investigator Assessment for MONALEESA-2 (02-Jan-17 cut-off)

	Ribociclib plus letrozole N=334	Placebo plus letrozole		
		N=334		
Progression free survival				
Median [months] (95% CI)	25.3 (23.0-30.3)	16.0		
		(13.4-18.2)		
Hazard ratio (95% CI)	0.568 (0.457-0.704)			
p-value <sup>a</sup>	9.63×10 <sup>-8</sup>			

CI=confidence interval; N=number of patients;

<sup>*a*</sup>*p*-value is obtained from the one-sided stratified log-rank test.

# Figure 1 Kaplan-Meier plot of PFS based on Investigator assessment – MONALEESA-2 (Full analysis set -02-Jan-17 cut-off)



KISQALI<sup>®</sup> ribociclib (as ribociclib succinate)

In patients with measurable disease, the overall response rate according to local radiologist assessment was 52.7% of patients (95% CI: 46.6%, 58.9%) in the KISQALI plus letrozole arm and 37.1% (95% CI: 31.1%, 43.2%) in the placebo plus letrozole arm.

# Figure 2 Forest plot of Subgroup analysis of PFS based on Investigator assessment – MONALEESA-2 (Full analysis set 02-Jan-17 cut-off)


Subgroup	No. of Patients		Hazard Ratio (95% Cl)
All patients	668	⊢ <b>∔</b> ⊣ ≟	0.57 (0.46 - 0.70)
Age			
<65 Years	373	⊢╇┤	0.52 (0.39 - 0.68)
>=65 Years	295	i li i i i i i i i i i i i i i i i i i	0.66 (0.47 - 0.93)
Race			
Asian	51	┝──┲─┼┤	0.37 (0.18 - 0.76)
non-Asian	568	⊢₌⊣	0.61 (0.49 - 0.78)
ECOG performance status			
0	407	⊢ <b>∔</b> -1 ≜	0.58 (0.44 - 0.77)
1	261	⊢┥┤	0.54 (0.39 - 0.77)
Hormone-receptor status			
ER and PR positive	546	⊢⊷	0.61 (0.47 - 0.77)
Other*	122	┝╼╾╢┊	0.36 (0.22 - 0.59)
Presence of liver or lung metastases			
No	295	┝╋╌┥┋	0.60 (0.43 - 0.84)
Yes	373	F+1	0.56 (0.42 - 0.74)
Bone-only disease			
No	521	┝╇┤┊	0.55 (0.43 - 0.70)
Yes	147		0.64 (0.39 - 1.05)
Newly diagnosed disease			
No	441	F <b>∳</b> 1 ∮	0.58 (0.45 - 0.75)
Yes	227	<b>⊢+</b> −1	0.57 (0.38 - 0.84)
Previous endocrine therapy			
NSAI and others+	53	┝━━╋╋	0.43 (0.21 - 0.90)
Tamoxifen or exemestane	295	⊢ <del>−</del>	0.52 (0.38 - 0.71)
None	320	F <del>1</del> ∎−1	0.65 (0.47 - 0.90)
Previous chemotherapy			
No	377	┝┼╾┤┊	0.64 (0.47 - 0.87)
Yes	291	┝╼╄┥	0.50 (0.37 - 0.68)
			>
		Ribociclib Better Place	oo Better

The global health status/QoL showed no relevant difference between the KISQALI plus letrozole arm and the placebo plus letrozole control arm.

A series of pre-specified subgroup PFS analyses was performed based on prognostic factors and baseline characteristics to investigate the internal consistency of treatment effect. A reduction in the risk of disease progression or death in favour of the ribociclib plus letrozole arm was observed in all individual patient subgroups of age, race, prior adjuvant or neo-adjuvant chemotherapy or hormonal therapies, liver and/or lung involvement and bone-only metastatic disease. This was evident for patients with liver and/or lung disease (HR; 0.561 [95% CI: 0.424, 0.743]), median progression-free survival [mPFS] 24.8 months vs 13.4 months respectively for the ribociclib and placebo arms respectively; the same benefit was observed for those patients, without liver and/or lung disease (HR; 0.597 [95% CI: 0.426, 0.837], mPFS 27.6 months versus 18.2 months).

# Final Overall Survival analysis

At the time of the final overall survival (OS) analysis (10-Jun-2021 cut-off), the study met its key secondary endpoint, and showed superior efficacy with statistically significant and clinically meaningful improvement in OS with a 23.5% relative reduction in risk of death (HR: 0.765, 95% CI: 0.628, 0.932; p-value=0.004); see Figure 3.



# Figure 3 MONALEESA-2 (A2301) Kaplan-Meier plot for OS (FAS) (data cut-off 10-Jun-2021)

One sided P-value is obtained from stratified log rank test.

Additionally, the median time to first subsequent chemotherapy was prolonged by 11.7 months in the KISQALI arm compared to the placebo arm (50.6 months, 95% CI: 38.9, 60.0 months vs 38.9 months, 95% CI: 31.4, 45.4).

# Study CLEE011A2404 (COMPLEEMENT-1)

Study #	Trial design	Dosage, route of administration and duration	Study subjects	Mean age (Range)	Gender
LEE011 A2404 (Phase IIIb)	Open-label, multicenter, study of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopa usal women with HR-positive, HER2-negative advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease	Route of Administration: Oral Dosage: Ribociclib (600 mg/day p.o. 3 weeks on and 1 week off + Letrozole (2.5 mg/day p.o. once daily for 28 days) + Goserelin (3.6 mg every 28 days s.c. or leuprolide 7.5 mg every 28 days i.m. (only for premenopausal women and men)) Median duration of exposure to the study treatment was 20.8 months in the male patients.	A total of 3246 patients with advanced breast cancer were enrolled. N (male) = 39 N (female) = 3207	Male Median: 62 years (range: 33 to 80) Female Median: 58 years (range: 20-92)	Male and Female

#### Table 17 - Summary of patient demographics for COMPLEEMENT-1

KISQALI was evaluated in an open-label, single arm, multicenter phase IIIb clinical study comparing ribociclib in combination with letrozole in men and pre/post-menopausal women with HR-positive, HER2-negative, advanced breast cancer who received no prior hormonal therapy for advanced disease. Premenopausal women, and men, also received goserelin or leuprolide.

The study enrolled 3246 patients, including 39 male patients, who received KISQALI 600 mg orally once daily for 21 consecutive days followed by 7 days off; and letrozole 2.5 mg orally once daily for 28 days; and goserelin 3.6 mg as injectable subcutaneous implant or leuprolide 7.5 mg as intramuscular injection administered on Day 1 of each 28 day cycle. Patients were treated until disease progression or unacceptable toxicity occurred.

Male patients enrolled in this study had a median age of 62 years (range 33 to 80). Of these patients, 38.5% were 65 years and older, including 10.3% aged 75 years and older. The male patients enrolled were Caucasian (71.8%), Asian (7.7%), and Black (2.6%), with 17.9% unknown. Nearly all male patients (97.4%) had an ECOG performance status of 0 or 1. The majority of male patients (97%) had 4 or less metastatic sites, which were primarily bone and visceral (69.2% each). Table 18 summarizes the efficacy results in male patients.

# **Study Results**

# Table 18COMPLEEMENT-1 (A2404) efficacy results in male patients<sup>1</sup> based on investigator<br/>assessment (intent-to-treat population)

	KISQALI + Letrozole + Goserelin or Leuprolide
	N=39
<b>Overall Response Rate*</b> Number of patients with confirmed CR or PR : Total number of patients with measurable disease at baseline	15: 32 (46.9 %)
(95% CI)	(29.1, 65.3)
Duration of Response <sup>1</sup>	2: 15 (13.3%)
Number of patients with PD : Number of patients with confirmed CR or PR	
Median (months)	NR
95% CI	(21.3, NR)
Number of patients with $DOR \ge 12$ months: Number of patients with confirmed CR or PR	12:15 (80.0%)
Clinical Benefit Rate <sup>2</sup>	
Number of patients with confirmed CR or PR or prolonged SD : Total number of patients with measurable disease at baseline	23: 32 (71.9%) (53.3, 86.3)
(95% CI)	

Abbreviations: CI, confidence interval, NR, not reached.

\*Based on confirmed responses.

<sup>1</sup>Number of events in patients with confirmed complete response (CR) or partial response (PR).

<sup>2</sup>Proportion of patients with complete response + partial response + (stable disease or non-complete response/non-progressive disease  $\geq$ 24 weeks)

# Study CLEE011E2301 (MONALEESA-7)

#### Table 19- Summary of patient demographics for MONALEESA-7

Study #	Trial design	Dosage, route of administration and duration	Study subjects	Mean age (Range)	Gender
LEE011 E2301	A Phase III randomized, double-blind, placebo- controlled study comparing ribociclib plus goserelin plus either tamoxifen or a NSAI (letrozole or anastrozole), (henceforth ribociclib arm) versus placebo plus goserelin plus either tamoxifen or a NSAI (letrozole or anastrozole) (henceforth placebo arm), in premenopausal women with HR- positive, HER2- negative advanced breast cancer who received no prior hormonal therapy for advanced breast cancer.	Route of Administration : Oral Dosage Ribociclib arm: Ribociclib (600 mg orally once daily, on Days 1- 21 of a 28-Day cycle) plus goserelin (3.6 mg subcutaneous implant on Day 1 of 28-day Cycle) plus either tamoxifen (20 mg orally once daily) or a NSAI (either letrozole 2.5 mg orally once daily or anastrozole 1 mg orally once daily). Dosage Placebo arm: Placebo (orally daily, on Days 1-21 of a 28-day cycle) plus goserelin (3.6 mg subcutaneous implant on Day 1 of 28-day Cycle) plus either tamoxifen (20 mg orally once daily) or a NSAI (letrozole 2.5 mg orally once daily or anastrozole 1 mg orally once daily). Duration of treatment: until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason. The median duration of follow- up (defined as the time from randomization to the data cut- off date) was 19.2 months (min- max: 12.6 - 32.1). The study is currently ongoing.	Total of 672 Randomized 1:1 335 patients in ribociclib arm and 337 patients in placebo arm. All randomized patients received study treatment.	Median age of patients in the study was 44 years (min to max: 25 to 58) and 72.3% were $\geq$ 40 years of age. Ribociclib arm: median age was 43 years (min to max: 25 - 58) and 70.7% were $\geq$ 40 years of age. Placebo arm: median age was 45 years (min to max: 29 - 58) and 73.9% were $\geq$ 40 years of age.	Pre- or Peri menopausal women with HR-positive, HER2- negative advanced breast cancer who received no prior hormonal therapy for their advanced disease

Study CLEE011E2301 was a randomized, double-blind, placebo-controlled multicenter phase III clinical study comparing KISQALI plus either a non-steroidal aromatase inhibitor (NSAI) or tamoxifen and goserelin versus placebo plus either a NSAI or tamoxifen and goserelin for the treatment of pre- and perimenopausal women with (HR)-positive, HER2-negative, advanced breast cancer.

A total of 672 patients were randomized 1:1 to receive KISQALI 600 mg plus NSAI or tamoxifen plus goserelin (n= 335) or placebo plus NSAI or tamoxifen plus goserelin (n= 337), stratified according to the presence of liver and/or lung metastases, prior chemotherapy for advanced disease, and endocrine combination partner (NSAI and goserelin versus tamoxifen and goserelin). Demographics and baseline

disease characteristics were balanced and comparable between study arms.

Tamoxifen 20 mg or NSAI (letrozole 2.5 mg or anastrozole 1 mg) were given orally once daily on a continuous schedule; goserelin 3.6 mg was administered as sub-cutaneous injection on day 1 of each 28 day cycle, with either KISQALI 600 mg or placebo given orally once daily for 21 consecutive days followed by 7 days off until disease progression or unacceptable toxicity. Patients were not allowed to cross over from placebo to KISQALI during the study or after disease progression. Patients were not allowed to switch between endocrine combination partners.

Patients enrolled in the study had a median age of 44 years (range 25 to 58) and 27.7% of patients were younger than 40 years of age. The majority were Caucasian (57.7%), Asian (29.5%), or Black (2.8%) and nearly all patients (99.0%) had an ECOG performance status of 0 or 1. Of these 672 patients, 14.0% had received prior chemotherapy for metastatic disease. Of the 672 patients, 32.6% of patients had received chemotherapy in the adjuvant vs 18.0% in the neo-adjuvant setting and 39.6% had received endocrine therapy in the adjuvant vs 0.7% in the neo-adjuvant setting prior to study entry. Approximately 40.2% of patients had *de novo* metastatic disease, 23.7% had bone only disease, and 56.7% had visceral disease.

# **Primary analysis**

The primary efficacy endpoint for the study was met after observing 318 progression-free survival (PFS) events using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, based on the investigator assessment in the full analysis set, and supported by a blinded independent central radiological assessment.

The median follow-up duration at the time of the primary PFS analysis was 19.2 months.

In the pre-specified subgroup analysis of 495 patients who had received KISQALI or placebo in combination with NSAI plus goserelin, the median PFS was 27.5 months (19.1, not estimable (NE)) in the KISQALI plus NSAI subgroup and 13.8 months (12.6, 17.4) in the placebo plus NSAI population [HR: 0.569 (95% CI: 0.436, 0.743)], which was consistent with the overall study population regardless of combination partner. Efficacy results are presented in Table 20 and the Kaplan-Meier curve for PFS in Figures 4 and 5. Results in the KISQALI plus NSAI population were consistent across subgroups of age, race, prior adjuvant/ neo-adjuvant chemotherapy or hormonal therapies, liver and/or lung involvement and bone only metastatic disease (Figure 6).

The global health status /QoL showed no relevant difference between KISQALI compared with placebo.




 Table 20
 CLEE011E2301 efficacy results based on investigator assessment in patients who received NSAI - MONALEESA-7 (20-Aug-17 cut-off)

Analysis	Ribociclib plus NSAI plus goserelin (%, 95% CI)	Placebo plus NSAI plus goserelin (%, 95% Cl)	
Progression- free survival <sup>c</sup>	N=248	N=247	
Median [months] (95% CI)	27.5 (19.1, NE)	13.8 (12.6, 17.4)	
Hazard ratio (95% CI)	0.569 (0.436, 0.743)		
Patients with measurable disease	N=192	N=199	
Overall Response Rate <sup>a</sup>	50.5 (43.4 , 57.6)	36.2 (29.5 , 42.9)	

<sup>a</sup>ORR: proportion of patients with complete response + partial response Cl=confidence interval; N=number of patients; NE = Not estimable.

# Figure 5 Kaplan-Meier plot of PFS based on investigator assessment in patients who received NSAI – MONALEESA-7 (20-Aug-17 cut-off)




Figure 6 Forest plot of PFS based on investigator assessment in patients who received NSAI<sup>1</sup> (20-Aug-17 cut-off)

	Events (n)	/patients	(N)		HR (95% CI)
	Ribociclib group	Placebo group	Total		
Endocrine therapy partner	r				
Tamoxifen	39/87	55/90	94/177	<b>+</b>	0.59 (0.39–0.88)
NSAI	92/248	132/247	224/495	_ <b>\</b>	0.57 (0.44–0.74)
Age					
<40 years	42/98	61/88	103/186		0.44 (0.29-0.67)
≥40 years	89/237	126/249	215/486	_ <b>\</b>	0.59 (0.45-0.78)
Race					
Asian	33/99	62/99	95/198	<b>_</b>	0.40 (0.26-0.63)
Non-Asian	84/200	112/213	196/413		0.66 (0.49–0.88
Region					
Asia	33/92	56/88	89/180	<b>_</b>	0.42 (0.27-0.66)
Europe and Australia	55/136	75/139	130/275		0.63 (0.44-0.91)
Latin America	12/31	11/25	23/56		0.76 (0.31-1.86)
North America	19/47	27/50	46/97		0·54 (0·29–1·01)
Other	12/29	18/35	30/64		0.84 (0.39-1.82)
ECOG performance status					
0	87/245	134/255	221/500	_ <b>_</b>	0.55 (0.42-0.72)
≥1*	43/87	51/79	94/166	<b>•</b>	0·50 (0·32–0·77)
Hormone receptor status					
ER and PR positive	105/286	149/286	254/572	_ <b>\</b>	0.57 (0.45-0.74)
Other	26/49	38/51	64/100		0.44 (0.26-0.77)
Presence of liver or lung m	etastases				
Yes	75/173	109/170	184/343	_ <b>_</b>	0.50 (0.38-0.68
No	56/162	78/167	134/329	<b>_</b>	0.64 (0.45-0.91
Bone-only disease					
Yes	25/81	33/78	58/159		0·70 (0·41–1·19)
No	106/254	154/259	260/513	_ <b>—</b>	0.53 (0.42-0.69)
Number of metastatic site	s				
<3	76/219	106/216	182/435	_ <b>—</b>	0.60 (0.44–0.81
≥3	55/116	81/121	136/237	<b>+</b>	0.50 (0.35-0.72)
Prior chemotherapy for ad	vanced disea	se			
Yes	22/47	29/47	51/94		0.55 (0.31-0.95)
No	109/288	158/290	267/578	_ <b>_</b>	0.57 (0.44-0.72)
Prior neoadjuvant or adjuv	ant chemot	nerapy			
Yes	64/138	76/138	140/276	<b>.</b>	0.68 (0.48–0.96
No	45/150	82/152	127/302	<b>+</b> _	0.41 (0.28-0.60)
Prior neoadjuvant or adjuv	vant endocrii	ne therapy			
Yes	58/127	79/141	137/268	<b>\</b>	0·62 (0·44–0·89
No	73/208	108/196	181/404	<b>_</b>	0.52 (0.38-0.70)
Disease-free interval after	diagnosis				
≤12 months	15/23	9/13	24/36		0.56 (0.21-1.49)
>12 months	76/176	106/190	182/366	<b>\</b>	0.62 (0.46-0.83
Newly diagnosed disease	40/136	72/134	112/270		0.43 (0.29-0.64
Treatment-free interval af endocrine therapy	ter neoadjuv	ant or adju	vant		
≤12 months	51/100	65/105	116/205		0.59 (0.40-0.87
>12 months	7/25	14/35	21/60		0.75 (0.28-2.02)
All patients	131/335	187/337	318/672		0.55 (0.44-0.69
			0.12	5 0.25 0.5 0 2	4 8
			Fa	vours ribociclib Favours p group grou	

All subgroup analyses presented were prespecified in the protocol. The size of the data points is proportional to the number of patients included in the subgroup analysis. ECOG=Eastern Cooperative Oncology Group. ER=oestrogen receptor. HR=hazard ratio. NSAI=non-steroidal aromatase inhibitor. PR=progesterone receptor. \*One patient had an ECOG performance status of 2.


<sup>1</sup>KISQALI is not indicated for use in combination with tamoxifen and combined treatment is not recommended.

# **Final Overall Survival Analysis**

At the time of the second (final) prespecified OS analysis (30-Nov-2018 cut-off), the study met its key secondary endpoint of OS, demonstrating a statistically significant improvement in OS (HR: 0.712; 95% CI: 0.535, 0.948; one-sided stratified log-rank test p-value: 0.00973), and was consistent for the NSAI population (Figure 6) and across exploratory subgroups. Median OS was not reached in the KISQALI arm and was 40.9 months (95% CI: 37.8, NE) in the placebo arm. The median duration of follow-up was 34.6 months.

These data suggest an estimated relative risk reduction of death of approximately 29% in the KISQALI arm compared to the placebo arm.





Hazard ratio is based on unstratified Cox model.

The median time to progression on next-line therapy or death (PFS2) in the NSAI population was 32.3 months (26.9, 38.3) in the placebo arm and was not reached (39.4, NE) in the KISQALI arm [HR:0.660 (CI: 0.503, 0.868)].

# In combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.

# Study CLEE011F2301 (MONALEESA-3)

Study #	Trial design	Dosage, route of administration and duration	Study subjects	Mean age (Range)	Gender
LEE011 F2301	A randomized double-blind, placebo- controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2 negative, advanced breast cancer who have received no or only one line of prior endocrine treatment.	Route of Administration : Oral Dosage: Ribociclib (600 mg orally once daily on Days 1-21 of a 28-day cycle) plus fulvestrant (500 mg intramuscular [im] injection on Cycle 1 Days 1 and 15 and on Day 1 of subsequent cycles). Placebo (orally once daily on Days 1-21 of a 28-day cycle) plus fulvestrant (500 mg im injection on Cycle 1 Days 1 and 15 and on Day 1 of subsequent cycles). Duration until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.	726 patients were randomized 2:1 with 484 patients in the ribociclib plus fulvestrant arm and 242 patients in the placebo plus fulvestrant arm. 2 patients never received study treatment.	Median age of patients in the study was 63 years (min to max: 31 to 89); 46.7% were ≥ 65 years of age and 13.8 were ≥ 75 years of age. Ribociclib arm: Median age was 63 years (min to max: 31 to 89). Placebo arm: Median age was 63 years (min to max: 34 to 86).	Men and Post menopausal women

MONALEESA-3 was a randomized double-blind, placebo controlled study of KISQALI in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment.

A total of 726 patients were randomized in a 2:1 ratio to receive KISQALI 600 mg and fulvestrant (n= 484) or placebo and fulvestrant (n= 242), stratified according to the presence of liver and/or lung metastases and prior endocrine therapy for advanced or metastatic disease. First-line patients with advanced breast cancer (A) include de novo advanced breast cancer with no prior endocrine therapy, and patients who relapsed after 12 months of (neo) adjuvant endocrine therapy completion.

Second-line patients' subgroup (B) includes those patients whose disease relapsed during adjuvant therapy or less than 12 months after endocrine adjuvant therapy completion, and those who progressed to first line endocrine therapy. Demographics and baseline disease characteristics were balanced and comparable between study arms. KISQALI 600 mg or placebo was given orally daily for 21 consecutive days followed by 7 days off treatment in combination with fulvestrant 500 mg administered intramuscularly on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter.

Patients enrolled in this study had a median age of 63 years (range 31 to 89); 46.7% of patients were 65 years and older, including 13.8% of patients 75 years of age and older. The patients included were Caucasian (85.3%), Asian (8.7%), or Black (0.7%). Nearly all patients (99.7%) had an ECOG performance status of 0 or 1. First- and second-line patients were enrolled in this study (of whom 19.1% of patients had *de novo* metastatic disease). Approximately 43% of patients had received chemotherapy in the adjuvant vs 13.1% in the neo-adjuvant setting and 58.5% had received endocrine therapy in the adjuvant vs 1.4% in the neo-adjuvant setting prior to study entry, Approximately 21% of patients had bone-only disease and 60.5% of patients had visceral disease.

# Primary analysis

The primary efficacy endpoint for the study was assessed after observing 361 progression-free survival (PFS) events using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), based on the investigator assessment in the full analysis set. The median follow-up duration at the time of primary PFS analysis was 20.4 months.

The primary efficacy results demonstrated a statistically significant improvement in PFS in patients receiving KISQALI plus fulvestrant compared to patients receiving placebo plus fulvestrant with an estimated 41% reduction in relative risk of progression or death in favor of the KISQALI plus fulvestrant arm (HR = 0.593, 95% CI: 0.480, 0.732, one-sided stratified log rank test p-value = 0.00000041). The descriptive updated PFS results support the primary PFS analyses.

PFS analyses based on the blinded independent central radiological assessment (hazard ratio 0.492) were supportive of the primary efficacy results.

In patients with measurable disease, the overall response rate according to local radiologist assessment was 40.9% of patients (95% CI: 35.9%, 45.8%) in the KISQALI plus fulvestrant arm and 28.7% (95% CI: 22.1%, 35.3%) in the placebo plus fulvestrant arm with a reported p-value of 0.003.

Results were consistent across pre-specified sub-groups of age, prior adjuvant or neo-adjuvant chemotherapy or hormonal therapies, liver and/or lung involvement, bone-only metastatic disease. The subgroup analysis is presented in a Forest Plot in Figure 8.

# Figure 8 Forest plot of primary PFS results based on investigator assessment (FAS) (03 Nov 17 cut-off) – Study CLEE011F2301

Events, n/N (%)							
Subgroup		Ribociclib plus fulvestrant	Placebo plus fulvestrar	Favors ribociclib	Favors placebo	Hazard ratio	95% CI
All patients		210/484 (43)	151/242 (62)	нфн		0.593	0.480 to 0.732
Prior endocrine therapy*	Treatment naïve Up to one line	76/238 (32) 131/236 (56)	66/129 (51) 84/109 (77)			0.577 0.565	0.415 to 0.802 0.428 to 0.744
Liver or lung involvement	Yes No	116/242 (48) 94/242 (39)	77/121 (64) 74/120 (62)	⊢		0.645 0.563	0.483 to 0.861 0.415 to 0.764
Bone lesion only	Yes No	36/103 (35) 174/381 (46)	35/51 (69) 116/190 (61)			0.379 0.658	0.234 to 0.613 0.519 to 0.833
Age, years	< 65 ≥ 65	115/258 (45) 95/226 (42)	81/129 (63) 70/113 (62)			0.607 0.597	0.454 to 0.810 0.436 to 0.818
Race	Asian White Other	22/45 (49) 174/406 (43) 8/18 (44)	7/18 (39) 136/213 (64) 3/6 (50)			1.353 0.562 0.881	0.574 to 3.186 0.448 to 0.704 0.199 to 3.907
ECOG PS	0 1	126/310 (41) 83/173 (48)	95/158 (60) 56/83 (67)	⊢∳⊣		0.559 0.633	0.427 to 0.73 0.450 to 0.89
No. of metastatic sites	< 3 ≥ 3	126/309 (41) 84/175 (48)	92/149 (62) 59/92 (64)			0.586 0.621	0.447 to 0.768 0.441 to 0.874
Prior tamoxifen	Yes No	79/193 (41) 131/291 (45)	63/104 (61) 88/137 (64)	⊢∳-I ⊢∳-I		0.620 0.562	0.443 to 0.866 0.428 to 0.738
Prior Al	Yes No	135/257 (53) 75/227 (33)	80/118 (68) 71/123 (58)	⊢∳⊣ ⊢∳⊣		0.670 0.481	0.507 to 0.886 0.345 to 0.669
				0.125 0.25 0.5 Hazard rat	1 2 4 io (95% CI)	8	

Progression-free survival outcomes in patient subgroups. Hazard ratios were estimated on the basis of stratified Cox proportional hazards model, except in subgroups related to stratification factors (presence or absence of lung or liver metastases and prior endocrine therapy), where an unstratified analysis was used. AI, aromatase inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status. (\*) Prior endocrine therapy for advanced disease; 14 patients were not included in the prior endocrine therapy subgroup analysis because of missing data or criteria not being met.

Since the median PFS for first-line patients had not been reached at the time of the primary analysis, a descriptive update of primary efficacy results (PFS) was performed at the time of the second OS interim analysis, and the updated PFS results are summarized in Table 22 and the Kaplan-Meier curve is provided in Figure 9.

# Table 22 MONALEESA-3 (F2301) descriptive updated PFS results (03-Jun-19 cut-off)


Overall population	Ribociclib plus fulvestrant	Placebo plus fulvestrant	
	N=484	N=242	
Number of events – n[%]	283 (58.5)	193 (79.8)	
Median PFS [months] (95% CI)	20.6 (18.6, 24.0)	12.8 (10.9, 16.3)	
Hazard ratio (95% CI)	0.587 (0.4	88, 0.705)	
First-line setting	Ribociclib 600 mg N=237	Placebo N=128	
Number of events – n [%]	112 (47.3)	95 (74.2)	
Median PFS [months] (95% CI)	33.6 (27.1, 41.3)	19.2 (14.9, 23.6)	
Hazard ratio (95% CI)	0.546 (0.415, 0.718)		
Second-line setting or with an early relapse	Ribociclib 600 mg N=237	Placebo N=109	
Number of events – n [%]	167 (70.5)	95 (87.2)	
Median PFS [months] (95% CI)	14.6 (12.5, 18.6)	9.1 (5.8, 11.0)	
Hazard ratio (95% CI)	0.571 (0.4	43, 0.737)	

CI=confidence interval

First-line setting = newly diagnosed (de novo) advanced breast cancer or relapse after 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for advanced or metastatic disease Second-line setting or with an early relapse = relapse on or within 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for advanced or metastatic disease (early relapse), relapse after 12 months from completion of (neo)adjuvant therapy with subsequent progression after one line of endocrine therapy for advanced or metastatic disease, or advanced or metastatic breast cancer at diagnosis that progressed after one line of endocrine therapy for advanced or metastatic disease with no prior (neo)adjuvant treatment for early disease

The global health status/QoL showed no relevant difference between KISQALI plus fulvestrant arm and the placebo plus fulvestrant arm.


# Figure 9 MONALEESA-3 (F2301) Kaplan-Meier plot of descriptive updated PFS based on investigator assessment (FAS) (03-Jun-19 cut off)



#### **Final OS Analysis**

At the time of the second interim OS analysis the study met its key secondary endpoint demonstrating a statistically significant improvement in OS for the overall population (Figure 10) and was consistent for the prior endocrine therapy subgroups (Figures 11, 12) and across all other subgroups.


Figure 10 MONALEESA-3 (F2301) Kaplan Meier plot of OS (FAS) (03-Jun-19 cut-off)




Log-rank test and Cox model are stratified by lung and/or liver metastasis, prior chemotherapy for advanced disease, and endocrine combination partner per IRT

KISQALI<sup>®</sup> ribociclib (as ribociclib succinate)


*P-value is one-sided and is compared against a threshold of 0.01129 as determined by the Lan-DeMets (O'Brien-Fleming) alpha-spending function for an overall significance level of 0.025.* 






Hazard ratio is based on unstratified Cox model

<sup>1</sup>*First-line setting = newly diagnosed (de novo) advanced breast cancer or relapse after 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for advanced or metastatic disease* 





KISQALI<sup>®</sup> ribociclib (as ribociclib succinate)

#### Hazard ratio is based on unstratified Cox model

<sup>1</sup>Second-line setting or with an early relapse = relapse on or within 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for advanced or metastatic disease (early relapse), relapse after 12 months from completion of (neo)adjuvant therapy with subsequent progression after one line of endocrine therapy for advanced or metastatic disease, or advanced or metastatic breast cancer at diagnosis that progressed after one line of endocrine therapy for advanced disease with no prior (neo)adjuvant treatment for early disease

Additionally, time to progression on next-line therapy or death (PFS2) in patients in the KISQALI arm was longer compared to patients in the placebo arm (HR: 0.670 (95% CI: 0.542, 0.830)) in the overall study population. The median PFS2 was 39.8 months (95% CI: 32.5, NE) for the KISQALI arm and 29.4 months (95% CI: 24.1, 33.1) in the placebo arm.

# 14.2 Comparative Bioavailability Studies

Study A2103 was a randomized, open-label, single-center, crossover study to evaluate the BE of a new tablet formulation of ribociclib in comparison to a capsule formulation of ribociclib and the effect of food following a single oral dose of 600 mg in healthy subjects.

# Table 23Study A2103

Ribociclib	
(3 x _200_ mg)	
From measured data	
Geometric Mean	

Parameter	Test	Reference	Ratio of Geometric Means	90% Confidence Interval (Lower, Upper)	
AUC⊤	10600	10600	1	(0.881, 1.14)	
(hr*ng/mL)	n=31	n=31	-	(0.001, 1.14)	
AUC	10800	11500	0.937	(0.885, 0.991)	
(hr*ng/mL)	n=31	n=30	0.337	(0.003, 0.331)	
Смах	601	596	1.01	(0.869, 1.17)	
(ng/mL)	n=31	n=31	1.01	(0.809, 1.17)	
T <sub>MAX</sub> (h)	3	3	0	(-4, 3)	
	n=31	n=31		( +, 3)	

Reference: 600mg LEE011 capsule, Test: 600mg LEE011 tablet.

- Model is a linear effects model of the log-transformed PK parameters. Included in the model were treatment,

period and sequence as fixed effects and subjects nested within sequences as a random effect.

- n = number of subjects with non-missing values.

 $-AUC_T = AUC_{last}$ 

- The analysis is conducted on log transformed PK parameters. Then the results are back transformed to get adjusted geo-mean, Geo-mean ratio, and 90% CI.

For T<sub>max</sub>, median is presented under 'Test' and 'Reference', median difference under 'Ratio of Geometric Means', and minimum and maximum differences under 90% CI.
 Source: Table 14.2-1.1a

# 15 MICROBIOLOGY

No microbiological information is required for this drug product.

# 16 NON-CLINICAL TOXICOLOGY

# DETAILED PHARMACOLOGY

# Pharmacodynamics

In biochemical assays, ribociclib inhibits CDK4/Cyclin D1 and CDK6/Cyclin-D3 enzyme complexes with IC50 values of 0.01  $\mu$ M (4.3 ng/mL) and 0.039  $\mu$ M (16.9 ng/mL), respectively. In a panel of serine/threonine and tyrosine kinases, inhibition of CDK4/D1 or CDK6/D3 was selective, ribociclib was inactive (IC50 >10  $\mu$ M) against 34 other serine/threonine and tyrosine kinases and showing weak inhibition (> 2.0  $\mu$ M) against Aurora A, HER1, and LCK with the IC50 values of 2.0  $\mu$ M, 9.0  $\mu$ M, and 7.7  $\mu$ M, respectively, further demonstrating its relative inactivity against kinases other than CDK4/6.

Ribociclib was a potent inhibitor of cell proliferation in a wide variety of cancer cell lines. A functional pRb protein was a requirement for the inhibition of cell proliferation. Cancer cell lines with genetic aberrations in the CDK4/6 signalling pathways were particularly susceptible to the anti-proliferative effects of ribociclib. The IC<sub>50</sub> value for cell proliferation inhibition by ribociclib in the mantle cell lymphoma cell line Jeko-2 with a translocation in the CCND1 gene (coding for cyclin D1) was 0.080  $\mu$ M and the IC<sub>50</sub> values for inhibition of phosphorylation of pRb and G1 arrest were 0.180 and 0.100  $\mu$ M, respectively. The IC<sub>50</sub> values for target phosphorylation of pRb, cell cycle assays and proliferation are similar and consistent with pRb phosphorylation tightly linked to G1 to S transition, with the inhibition of pRb phosphorylation leading to G1 arrest in cells. The main mode inhibition of cell proliferation was growth arrest and there were no significant cell death. In Jeko-1 cells, the metabolites M4 (LEQ803) and M13 (CCI28) were less potent inhibitors than ribociclib, with G1 arrest occurring at IC50 values of >13 times that of ribociclib.

Ribociclib was tested in a panel of 47 breast cancer cell lines annotated with ER status. Luminal ER+ breast cancer cell lines were most sensitive to ribociclib, with 16 of the 18 cell lines with IC50s < 1  $\mu$ M, while majority (21 out of 29) of the ER-negative cell lines have IC50s> 1  $\mu$ M.

In immunocompromised mice with established MCF7 ER+ human breast cancer xenograft model, ribociclib monotherapy at 75 mg/kg p.o., once per day resulted in exposure approximately similar to 400 mg to 600 mg once daily in human. Ribociclib treatment resulted in tumor regression with minimal effect on body weight. In immunocompromised mice with a patient-derived ER+ breast cancer xenograft model (PDX191), ribociclib at 75 mg/kg/day exhibited tumor growth inhibition which correlated with inhibition of pRb phosphorylation.

The anti-tumor efficacy of ribociclib and letrozole was assessed in immunocompromised mice using a primary ER+ breast cancer xenograft model derived from a patient tumor with a known sensitivity to letrozole. Ribociclib at 75 mg/kg combined with letrozole at 2.5 mg/kg, both dosed orally every day for 55 days, induced greater tumor growth inhibition than each agent alone. The combination of ribociclib and letrozole demonstrated statistically significant antitumor activity with complete tumor growth

inhibition, 2 out of 10 partial and 2 out of 10 complete tumor regressions. Tumor growth delay after stopping dosing was also observed.

# **Secondary Pharmacodynamics**

Ribociclib and LEQ803 were assessed for their off-target activity on respectively 147 and 144 G proteincoupled receptors (GPCRs), transporters, ion channels, nuclear receptors and enzymes.

For ribociclib, activities were found on phosphodiesterase PDE4d (IC50= 0.59  $\mu$ M, n=2), rat vesicular monoamine transporter VMAT2 (IC50 = 6.3  $\mu$ M, n=2), orexin-2 receptor (70% inhibition at 10  $\mu$ M) and apelin receptor (54% inhibition at 10  $\mu$ M). IC<sub>50</sub> values were not determined for the last two mentioned targets.

For LEQ803, activities were found on phosphodiesterase PDE4d (IC50 =  $0.6 \mu$ M), serotonin 5HT3 channel (IC50 =  $2.63 \mu$ M), neuronal nicotinic alpha 2 channel (IC50 =  $5.7 \mu$ M), cannabinoid CB1 receptor (IC50 =  $28 \mu$ M), peripheral rat imidazoline I2 receptor (71% inhibition at 10  $\mu$ M), rabbit monoamine transporter VMAT2 (84% inhibition at 10  $\mu$ M) and rat brain sodium channel site II (70% inhibition at 10  $\mu$ M). IC50 values were not determined for the last three mentioned targets.

The clinical free  $C_{max}$  at the recommended dose of 600 mg ribociclib was 1.2  $\mu M$ , and the free  $C_{max}$  of LEQ803 was 0.03  $\mu M.$ 

Given the absence of brain penetration by ribociclib following oral administration and intracarotid injection in rats, centrally-mediated effects resulting from interactions with targets expressed in the central nervous system (VMAT-2, PDE4d, serotonin 5-HT3, rat brain sodium channel site II, neuronal nicotinic alpha 2 channel receptors, orexin receptor OX2 and cannabinoid CB1 receptors) are unlikely to develop in humans.

# Safety pharmacology

Ribociclib caused a concentration-dependent decrease in hERG potassium channel currents in stably transfected HEK293 cells with an estimated IC50 of up to  $53.0 \ \mu$ M.

Ribociclib caused a concentration-dependent inhibition of the Nav1.5 sodium channel currents in stably transfected HEK293 cells with an IC50 of 24  $\mu$ M.

LEQ803, a major metabolite of ribociclib, caused a concentration-dependent suppression of hERG channel currents in stably transfected HEK293 cells with an IC50 of  $4.5\mu$ M.

In vivo cardiac safety studies in dogs demonstrated dose and concentration related QTc interval prolongation at exposures that would be expected to be achieved in patients following the recommended dose of 600 mg. Increased premature ventricular contractions (PVCs) were reported in a dog receiving a single oral dose of 100 mg/kg (resulting an exposure approximately 5-fold the clinical  $C_{max}$ ).

# TOXICOLOGY

# **Repeated dose toxicity**

The repeat dose toxicity was characterized in dogs and rats at doses up to and including maximum tolerated dose. In the dog, body weight loss, vomiting and severe liver/gall bladder toxicity occurred at 25 and 20 mg/kg/day in 2 and 4 week study. In the rat there were 2 potentially ribociclib related deaths in male rats after  $\geq$ 17 weeks of dosing at 150 mg/kg/day. Both animals had irregular respiration and microscopically there were increased alveolar macrophage infiltrates.

Mild to moderate decreases in circulating red and white blood cells correlated with bone marrow hypocellularity and lymphoid tissue findings (atrophy/lymphoid depletion) in dogs and rats in studies ranging from 2 to 27 weeks in rats and 2 to 39 weeks in dogs. These changes as well as findings in intestinal mucosa (atrophy), skin (atrophy) and bone (decreased bone formation) in dog in the 2 and 4 week studies and are considered related to the pharmacological mechanism of action. They were reversible or partially reversible after 4 weeks without treatment.

Testicular changes with seminiferous tubule degeneration and secondary effects in the epididymis with reduced luminal sperm with luminal cellular debris and epithelial vacuolation were noted in rats and dogs. In the 15- and 27-week rat studies, the NOAEL was 25 mg/kg/day, while in the 15- and 39-week studies in the dog, a NOAEL was not identified ( $\leq 1$  mg/kg/day). After a 4 week withdrawal period, the changes were consistent with partial recovery. The withdrawal period, given the length of the spermatogenic cycle, was not long enough for complete recovery.

Kidney changes, consisting of degeneration/regeneration of tubular epithelial cells, were noted in male rats only at  $\geq$ 75 mg/kg/day in the 15 and 27 week studies. Vacuolation of bile duct epithelium was noted in males at 150 mg/kg/day after 4 and 15 weeks, in males at  $\geq$ 75 mg/kg/day and in females at 300 mg/kg/day after 27 weeks of dosing. Increased incidence and severity of alveolar macrophage infiltrates in the lung of males at  $\geq$ 75 mg/kg/day in the 4 week study, at 150 mg/kg/day in the 15 week study, and at  $\geq$ 75 mg/kg/day in the 27 week study, as well as at 300 mg/kg/day in females in the 27 week study. The changes in kidney, bile duct and lung were reversible after a 4 week withdrawal period.

The pathogenesis of the bile duct toxicity, lymph node histiocytosis and lung macrophage infiltrates in the rat was suggested to be due to phospholipidosis. Liver/bile ducts/gallbladder was also identified as a target organ of toxicity for ribociclib in the dog. Findings in the dog included proliferative changes, cholestasis, sand-like gallbladder calculi, and inspissated bile and the proliferative changes within the intra- and extra-hepatic biliary tree may be indicative of irritation as a consequence of excretion of ribociclib and/or its metabolites via the biliary system. Mass balance data in rats and dogs show that the majority of ribociclib-related radioactivity is eliminated by metabolism via hepatic metabolism and biliary excretion.

The ribociclib exposures at the maximal feasible dose in repeat dose studies in rats and dogs were generally less than or similar to exposure in patients at MRHD. Thus, even for findings where NOAELs were identified, ribociclib exposure was less than clinical exposure at MRHD.

# **Reproductive Toxicity/Fertility**

A fertility study in male rats has not been performed, however ribociclib general toxicology studies clearly identified the testes as a target tissue in rats and dogs (see Repeated Dose Toxicity) and reduced fertility or infertility is to be expected in males.

In a fertility study in female rats, ribociclib did not affect the reproductive function, fertility or early embryonic development at any dose up to 300 mg/kg/day (approximately 0.6 times the clinical exposure in patients at the highest recommended dose of 600 mg/day based on AUC).

In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of ribociclib up to 1,000 mg/kg/day and 60 mg/kg/day, respectively, during the period of organogenesis.

In rats, 1,000 mg/kg/day was lethal in the maternal animals with embryofetal mortality. At 300 mg/kg/day, a slight, non-adverse trend towards reduced maternal body weight gain and fetal toxicity evidenced by reduced fetal weights accompanied by skeletal changes were considered to be transitory

and/or related to the lower fetal weights. There were no effects upon embryo-fetal mortality or adverse effects on fetal morphology at 50 or 300 mg/kg/day. The no-observed-adverse-effect level (NOAEL) for maternal toxicity was considered to be 300 mg/kg/day. The no-observed-effect-level (NOEL) for embryo-fetal development was considered to be 50 mg/kg/day.

In rabbits at doses of 30 and 60 mg/kg/day, there were adverse effects on embryo-fetal development as evidenced by increased incidences of fetal abnormalities (malformations and external, visceral and skeletal variants) and fetal growth (lower fetal weights). These findings included reduced/small lung lobes and additional vessel on the aortic arch and diaphragmatic hernia, absent accessory lobe or (partly) fused lung lobes and reduced/small accessory lung lobe (30 and 60 mg/kg), extra/rudimentary 13<sup>th</sup> ribs and misshapen hyoid bone and reduced number of phalanges in the pollex. There was no evidence of embryo-fetal mortality. The no-observed-effect level (NOEL) for maternal toxicity was 30 mg/kg/day and the NOEL for the embryo-fetal development was 10 mg/kg/day.

At 300 mg/kg/day in rats and 30 mg/kg/day in rabbits, the maternal systemic exposures (AUC) were lower than or at 1.5 times that achieved in patients at the highest recommended dose of 600 mg/day. Animal/human exposure margins at the no-effect doses for embryofetal toxicity in both species were well below therapeutic levels.

In lactating rats administered a single dose of 50 mg/kg, exposure to ribociclib was 3.56 fold higher in milk than in maternal plasma.

# Carcinogenicity:

Ribociclib was assessed for carcinogenicity in a 2-year rat study.

Oral administration of ribociclib for 2 years resulted in an increased incidence of endometrial epithelial adenocarcinoma and glandular and squamous hyperplasia in the uterus/cervix of female rats at doses  $\geq$ 300 mg/kg/day as well as an increased incidence in follicular tumors in the thyroid glands of male rats at a dose of 50 mg/kg/day. Mean exposure at steady state (AUC<sub>0-24h</sub>) in female and male rats in whom neoplastic changes were seen was 1.2- and 1.4-times that achieved in patients at the recommended dose of 600 mg/day, respectively. Mean exposure at steady state (AUC<sub>0-24h</sub>) in female and male rats in whom neoplastic changes were seen was 2.2- and 2.5-times that achieved in patients at a dose of 400 mg/day, respectively.

Additional non-neoplastic proliferative changes consisted of increased liver altered foci (basophilic and clear cell) and testicular interstitial (Leydig) cell hyperplasia in male rats at doses of  $\geq$ 5 mg/kg/day and 50 mg/kg/day, respectively. Mean exposure at steady state (AUC<sub>0</sub>-24h) was below and 1.4-times that achieved in patients at the recommended dose of 600 mg/day, respectively. Mean exposure at steady state (AUC<sub>0</sub>-24h) was below and 2.5-times that achieved in patients at a dose of 400 mg/day, respectively.

The effects on the uterus/cervix and on the testicular interstitial (Leydig) cell may be related to prolonged hypoprolactinemia secondary to CDK4 inhibition of lactotrophic cell function in the pituitary gland, altering the hypothalamus-pituitary-gonadal axis.

Potential mechanisms for the thyroid findings in males include a rodent-specific microsomal enzyme induction in the liver and/or a dysregulation of the hypothalamus-pituitary-testis-thyroid axis secondary to a persistent on-target hypoprolactinemia.

Any potential increase of estrogen/progesterone ratio in humans by this mechanism would be compensated by an inhibitory action of concomitant anti-estrogen therapy on estrogen synthesis as in humans. KISQALI is indicated in combination with estrogen-lowering agents.

Considering important differences between rodents and humans with regard to synthesis and role of prolactin, the consequence of CDK4 inhibition in this context in humans is unclear.

### Genotoxicity:

Ribociclib was not genotoxic *in vitro* in bacterial and mammalian cell assays with and without metabolic activation and in an *in vivo* study in rats.

### Phototoxicity:

Ribociclib was shown to absorb light in the UV-B and UV-A range. An *in vitro* phototoxicity test did not identify a relevant phototoxicity potential for ribociclib. The risk that ribociclib causes photosensitization in patients is considered low.

### PATIENT MEDICATION INFORMATION

# READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

### <sup>Pr</sup>KISQALI<sup>®</sup>

### ribociclib tablets

Read this carefully before you start taking **KISQALI**<sup>®</sup> and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **KISQALI**.

Your breast cancer may be treated with **KISQALI** in combination with another drug (aromatase inhibitors or fulvestrant). Read the Patient Medication Information for the other drug as well as this one.

#### **Serious Warnings and Precautions**

KISQALI should only be administered by a healthcare professional experienced in the use of anticancer drugs.

The following serious side effects have been seen in people taking KISQALI:

- **Heart problems:** chest pain or discomfort, heart palpitations, fast or slow heartbeat, dizziness, lightheadedness, fainting, sudden death
- Liver problems: itching, yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite
- Low levels of white blood cells: fever, sore throat, mouth ulcers or other signs of infections

### What is KISQALI used for?

KISQALI is used to treat breast cancer in adult patients, when it has spread to other parts of the body. The breast cancer must be hormone receptor positive and human epidermal growth factor receptor 2-negative. It is taken in combination with:

- aromatase inhibitors. This is an initial hormone therapy for women and men. Patients need to also take a drug to reduce the amount of estrogen (for women who have not gone through menopause) or testosterone (for men).
- fulvestrant. This is used as an initial hormone therapy or when other hormone therapies do not work. Women must have gone through menopause to take KISQALI this way.

### How does KISQALI work?

KISQALI belongs to a family of medications called kinase inhibitors. These medications work by stopping cancer cells from dividing and growing. KISQALI has to be used together with an aromatase inhibitor or with fulvestrant. When given together with one of these drugs, KISQALI may slow down the growth and spread of breast cancer cells.

### What are the ingredients in KISQALI?

Medicinal ingredient: ribociclib succinate

Non-medicinal ingredients: Colloidal silicon dioxide, crospovidone (Type A), iron oxide black (E172), iron

oxide red (E172), lecithin (soy) (E322), low-substituted hydroxypropylcellulose, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol (partially hydrolysed), talc, titanium dioxide (E171) and xanthan gum.

# KISQALI comes in the following dosage forms:

Tablets; 200 mg ribociclib (as ribociclib succinate)

### Do not use KISQALI if:

- you are allergic to ribociclib succinate or to any of the other ingredients of KISQALI.
- you have serious heart problems including a condition known as "congenital long QT syndrome".

# To help avoid side effects and ensure proper use, talk to your healthcare professional before you take KISQALI. Talk about any health conditions or problems you may have, including if you:

- have fever, sore throat or mouth ulcers due to infections (signs of low level of white blood cells).
- have or have ever had any problems with your liver or kidneys.
- have or have ever had heart problems, such as an irregular heartbeat, rate or rhythm, or low levels of potassium, magnesium, calcium or phosphorous in your blood.
- have a family history of sudden cardiac death.
- are dehydrated, suffer from persistent vomiting or an eating disorder.
- have diabetes.
- have a condition called "autonomic neuropathy" that causes problems with blood pressure, heart rate, sweating, bowel and bladder control and digestion.
- are taking any medicines or supplements.

### Other warnings you should know about:

### Pregnancy, breast-feeding and fertility

- If you are pregnant, still able to get pregnant, or think you are pregnant, there are specific risks you must discuss with your healthcare professional.
- Avoid becoming pregnant while taking KISQALI. It may harm your unborn baby.
- If you are able to become pregnant, your healthcare professional will make sure that you are not pregnant before starting KISQALI.
- Use effective birth control if you can get pregnant while taking KISQALI and for at least 21 days after your last dose. Ask your healthcare professional about ways to avoid becoming pregnant.
- You should not breastfeed while you are taking KISQALI or for 21 days after your last dose.

### Fertility in male patients

• KISQALI may reduce fertility in male patients, which may affect your ability to father a child. Talk to your healthcare professional if this is a problem for you.

**Driving and Using Machines:** KISQALI can cause fatigue and fainting. You should use caution when driving or operating potentially dangerous machinery while you are taking KISQALI.

### During your treatment with KISQALI, tell your healthcare professional straight away:

• If you have fever, chills, weakness and frequent infections with signs such as, sore throat or mouth ulcers. This could be due to a low level of white blood cells.

- If you have tiredness, itchiness, yellow skin, nausea, vomiting, yellowing of the whites of your eyes, loss of appetite, pain in the abdomen, dark or brown urine, or more than normal bleeding or bruising. These could be signs of problems with your liver.
- If you have chest pain or discomfort, changes in heart beat (faster or slower), palpitations, if your lips turn blue, if you feel lightheaded, dizzy or faint, if you have trouble breathing, or if your skin or your legs swell. These could be signs of problems with your heart.
- If you have trouble breathing, cough and shortness of breath. Tell your healthcare professional right away if you experience new or worsening symptoms. These could be signs of serious lung problems (pneumonitis/interstitial lung disease) during treatment that can lead to death.
- If you have a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms and enlarged lymph nodes (signs of serious skin reaction). Tell your doctor immediately if you experience new or worsening symptoms

# Children and adolescents (under 18 years old)

KISQALI is not to be used in children and adolescents under 18 years of age.

# Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

# The following may interact with KISQALI:

- Some medicines used to treat infections. These include medicines which treat fungal infections, such as ketoconazole, itraconazole, fluconazole, voriconazole, amphotericin B and posaconazole, or medicines which treat certain types of bacterial infections, such as telithromycin, clarithromycin, erythromycin, azithromycin, moxifloxacin, levofloxacin, ciprofloxacin and pentamidine
- Some medicines used to treat malaria such as quinine and chloroquine
- Some medicines used to treat HIV/AIDS such as ritonavir, saquinavir, indinavir, lopinavir, nelfinavir, telaprevir and efavirenz
- Some medicines used to treat seizures or fits (anti-epileptics) such as carbamazepine, phenytoin, rifampin and midazolam
- St. John's Wort, an herbal product used to treat depression and other conditions (also known as hypericum perforatum)
- Some medicines used to treat heart rhythm problems such as amiodarone, disopyramide, procainamide, quinidine, sotalol, ibutilide, dronedarone, flecainide and propafenone
- Some medicines used to treat heart problems such as ivabradine, beta-blockers, digitialis glycosides, non-dihydropyridine calcium channel blockers, cholinesterase inhibitors, alpha2-adrenoceptor agonists, If inhibitors and sphingosine-1 phosphate receptor modulators
- Some medicines used to treat high blood pressure such as verapamil and loop, thiazide and other diuretics ("water pills")
- Some medicines used to treat mental health problems such as olanzapine, chlorpromazine, pimozide, haloperidol, droperidol and ziprasidone
- Some medicines used to treat depression such as fluoxetine, citalopram, venlafaxine, amitriptyline, imipramine and maprotiline
- Some medicines used to treat migraines such as dihydroergotamine and ergotamine

- Some anesthetics used during surgery and pain medicines such as alfentanil, fentanyl and methadone
- Some medicines used to suppress the immune system in people who have had organ transplants such as cyclosporine, everolimus, sirolimus and tacrolimus
- Some medicines used to treat cancer such as ondansetron, sunitinib, nilotinib, ceritinib, vandetanib, arsenic trioxide and vorinostat
- Some medicines used to treat breathing problems, like asthma, such as salmeterol and formoterol
- Domperidone used to increase milk supply in breastfeeding mothers
- Anagrelide, used to treat high levels of blood platelets
- Corticosteroids, used to treat swelling and to suppress the immune system
- Proton Pump Inhibitors (PPIs), used to treat heartburn
- Laxatives and enemas
- Do not eat grapefruits or drink grapefruit juice while you are taking KISQALI.

Know the medicines you take. Keep a list of them to show your healthcare professional.

Ask your healthcare professional if you are not sure whether your medicine is one of the medicines listed above.

You should also tell your healthcare professional if you are prescribed a new medicine while taking KISQALI .

# How to take KISQALI:

Take KISQALI exactly as prescribed for you by your healthcare professional. They will tell you exactly how many tablets to take along with the other drugs and which days to take them on. Check with your healthcare professional if you are not sure. Do not change the KISQALI dose or schedule without talking to your healthcare professional.

Do not take more pills than the number prescribed by your healthcare professional.

You should not eat grapefruit or drink grapefruit juice while you are taking KISQALI. They may increase the amount of KISQALI in your blood and affect how KISQALI works.

- You should take KISQALI once daily, for 21 consecutive days. This is followed by 7 days offtreatment.
- Taking KISQALI at the **same time of day** will help you to remember when to take it. It is better to take KISQALI in the morning.
- KISQALI tablets should be **swallowed whole** (tablets should not be chewed, crushed or split prior to swallowing). No tablet should be taken if it is broken, cracked, or otherwise not intact.
- KISQALI tablets can be taken with or without food.

It is very important to follow your healthcare professional's advice. If you have certain side effects, your healthcare professional may ask you to take less medicine, to skip a dose or to stop treatment.

# Usual dose:

The usual starting dose is 600 mg orally (3 tablets of 200 mg) taken once daily for 21 consecutive days followed by 7 days off-treatment.

Continue taking KISQALI for as long as your healthcare professional tells you to. This is a long-term treatment, possibly lasting for months or years. Your healthcare professional will regularly monitor your condition to check that the treatment is working.

Stopping your treatment with KISQALI may cause your condition to become worse. Do not stop taking KISQALI unless your healthcare professional tells you to stop.

If you have any further questions on the use of KISQALI, ask your healthcare professional.

# Overdose:

If you think you, or a person you are caring for, have taken too much KISQALI, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

# Missed Dose:

If you miss a dose or vomit after taking your dose, skip the missed dose that day. Take the next dose at your regular time.

Do not take a double dose to make up for a forgotten or a missed dose. Instead, wait until it is time for your next dose and then take your usual prescribed dose.

### What are possible side effects from using KISQALI?

These are not all the possible side effects you may feel when taking KISQALI. If you experience any side effects not listed here, contact your healthcare professional.

### Some side effects are very common

- Pain: abdominal, back, neck, head
- Constipation
- Cough
- Dehydration
- Diarrhea
- Dizziness or light headedness
- Fever
- Hair loss or hair thinning
- Headache
- Itching
- Mouth sores or ulcers with gum inflammation
- Nausea, vomiting
- Rash
- Reduced appetite
- Shortness of breath, labored breathing

- Swollen hands, ankles or feet
- Tiredness
- Trouble sleeping
- Upset stomach, indigestion
- Weakness
- A sensation of losing balance
- Dry eyes, mouth or skin
- Loss of skin color in patches (vitiligo)
- Skin reddening
- Sore throat
- Strange taste in the mouth
- Eyes: Watering or tearing of eyes; blurry, vision, irritated eyes, swelling and redness of the inside of the eyelid (pink eye)
- Infection

**KISQALI** can cause abnormal blood test results and changes in the electrical signal of the heart. Your healthcare professional will do some tests before and during your treatment. They will tell you if your test results are abnormal and if you need treatment.

Serious side ef	fects and what to d	o about them	
Symptom / effect	Talk to your profes	Stop taking drug and get immediate	
	Only if severe	In all cases	medical help
VERY COMMON			
Anemia (low levels of red blood cells): fatigue, loss of energy, weakness, shortness of breath		v	
<b>Gastroenteritis</b> (infections of the stomach and intestines): Abdominal pain, diarrhea, nausea and vomiting			v
<b>Liver problems:</b> itchiness, yellow skin, nausea, vomiting, yellowing of the whites of your eyes, loss of appetite, pain in the abdomen, dark or brown urine, or more than normal bleeding or bruising			v
<b>Pneumonia</b> (infection in the lungs): chest pain when you breath or cough, confusion, cough which may produce phlegm, fatigue, fever, sweating and shaking chills, nausea, vomiting or diarrhea, shortness of breath			v
Urinary tract infection: pain and/or burning when urinating, blood in the urine, increased urge to urinate		v	
COMMON			
<b>Depression</b> (feelings of sadness or hopelessness that lasts for a long time)		v	
Fainting (syncope)			V
<b>Febrile neutropenia:</b> sore throat or mouth ulcers with a single episode of fever >38.3°C (or) above 38°C for more than one hour and/or with infection			v
Heart problems: chest pain or discomfort, heart palpitations, fast or slow heartbeat, dizziness, lightheadedness, fainting, sudden death			v

		I
Respiratory tract infections: runny or		
stuffy nose, sore throat, cough, sinus	v	
congestion, body aches, headache,		
sneezing, fever, generally feeling unwell		
Low levels of calcium in the blood:		
muscle cramps and spasms, numbness		V
and tingling in the hands, feet and face		
Low levels of platelets: spontaneous		V
bleeding or bruising		
Low levels of potassium in the blood:		V
irregular heartbeat, muscle weakness		
Vertigo (a sense of spinning dizziness)	V	
UNCOMMON		
Pulmonary embolism (blood clot in the		
lung): sudden, severe chest pain and		
trouble breathing, coughing up blood,		V
rapid breathing and heartbeat		
Sepsis and septic shock (infection of the		
blood): fever or dizziness, chills, high or		V
very low body temperature, little or no		
urine, low blood pressure, palpitations,		
rapid breathing, rapid heartbeat		
UNKNOWN	 	
Pneumonitis/ Interstitial lung disease		
(inflammation of the lung tissue):		V
Trouble breathing, cough and shortness		•
of breath, fever, feeling tired		
Severe skin reaction that might include		
a combination of: rash, red skin,		
blistering of the lips, eyes or mouth, skin		v
peeling, high fever, flu-like symptoms		v
and enlarged lymph nodes (toxic		
epidermal necrolysis (TEN))		
and enlarged lymph nodes (toxic		v

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

### **Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<u>https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html</u>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE:* Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

#### Storage:

- Keep this medicine out of the sight and reach of children.
- Do not take this medicine after the expiry date, which is stated on the box.
- Do not store above 30°C. Store in the original packaging to protect from moisture.
- Do not take this medicine if you notice any damage to the packaging or if there are any signs of tampering.

Ask your pharmacist how to dispose of medicines you no longer use.

### If you want more information about KISQALI:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<u>https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-product-database.html</u>); the manufacturer's website (<u>http://www.novartis.ca</u>) or by calling 1-800-363-8883.

This leaflet was prepared by Novartis Pharmaceuticals Canada Inc.

Last Revised Feb 10, 2023

KISQALI is a registered trademark.

Novartis Version: Mar 10, 2023